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ABSTRACT  
Pancreatic cancer is considered as the 4th most aggressive cancer in the Western 
world. There is a direct link between pancreatic cancer diagnosis and patient age with 
high occurrence of the disease happening in the 65-75-year age group. The majority of 
cases are diagnosed at the advanced stages, making curing of this disease unattainable 
and leading to high mortality rates. Problems related to treatment of cancer using 
traditional systemically delivered drugs are as a result of an ineffective absorption, 
bioavailability or high systemic toxicity resulting in unwanted side effects. Thus there is 
an unmet need for better, more efficient delivery systems causing an increased patient 
quality of life.  
In this work a poly(allylamine) graft polymer modified with 5-(4-chlorophenyl)-1,3,4-
oxadiazole-2-thiol hydrophobic pendant groups was developed. This polymer was 
capable of incorporation of metallic hybrid iron oxide-gold nanoparticles. The resultant 
magnetomicelles were capable not only of laser triggered heating but also carrying 
lipophilic drug molecules which we exploited in this work. In order to produce a heat 
triggered drug delivery system, a two new analogues of doxorubicin was created 
modifying the molecule with spermine or lipoic acid forming DOX-SP and DOX-LA 
respectively. 
Magnetomicelle synthesis was confirmed using nuclear magnetic resonance 
spectroscopy, inductively coupled spectra ʹ optical emission spectroscopy and fourier 
transform infrared spectroscopy. The aggregation behaviour was confirmed using 
photon correlation spectroscopy. Reversible drug incorporation was realised via 
linkage between the drug analogue linkers and the hybrid nanoparticle surface in the 
magnetomicelle. The magnetomicelles developed exhibited up to 59.21% drug release 
noticed at 44 °C after 24 h.  
Cytotoxicity of the doxorubicin analogue formulations was tested on human 
pancreatic adenocarcinoma (BxPC3) cells. The unloaded nano-aggregates were 
incubated for 24 h with the cells and the cell viability was compared to control wells. 
The result revealed that 50% of the total cell number was viable (IC50) at 50 gmL-1 
(PAA-Ox5-HNPs). These values revealed that the incorporation of the metallic HNPs 
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into the polymer backbone did not result in any significant increase in toxicity 
(p>0.001). 
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1.1 General Introduction 
1.1.1 Cancer   
Cancer is the uncontrolled proliferation of cells. A cell is the basic functional unit of all 
organisms.  In normal physiology, dead cells are replaced with new cells to sustain 
growth and development. This process is controlled by genes, and mutation of the 
genes can lead to cancer.  Cancer appears due to an accretion of mutations in the DNA 
over numerous cell divisions. Some of these mutations such as a mutation of the ) k-
ras) gene might cause uninterrupted cell division leading to the formation of tumours 
(Reckamp et al. 2016; Almoguera et al. 1988). Many reasons have been stated for the 
emergence of cancer. According to Doctor Jeff Yancey at the University of Utah Cancer 
Learning Centre, some factors responsible for cancer include unhealthy diet, smoking, 
exposure to toxic chemicals and UV  (Surh 2003; Yancik 2005; Moiseeva & Manson 
2009; Cancer Research 2016). 
1.1.1.1 Pancreatic cancer 
The pancreas Figure 1-1 is one of the most important organs of the body. It is linked to 
the small intestine, behind the stomach and in front of the backbone. The pancreas 
contains enzymes that are critical for the digestion of fat, starch, proteins and 
carbohydrates. These juices produced by the pancreas pass through a special channel 
to the first part and then to the second part of the small intestine (Bardeesy & 
DePinho 2002). 
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Figure 1-1: The pancreas location inside the body (Mayo foundation for medical 
education and research) 
 
Pancreatic secretion consists of mineral salts and water to stimulate digestion and 
balance of acid in the stomach (Bardeesy & DePinho 2002).  
Pancreatic cancer occurs as a result of genetic mutations that transform healthy cells 
into tumour cells. The increased death rates in pancreatic cancer are due to the rapid 
proliferation of the cancerous cell to other surrounding tissues. Pancreatic cancer is 
very difficult to diagnose due to lack of specificity of symptoms. Hence often patients 
are unaware until the late stages where treatment options are limited (Bardeesy et al 
2014) & (Mayo foundation for medical education and research). 
Pancreatic cancer Figure 1-2 has been shown to be resistant to most of the known 
anticancer agents. The treatment of pancreatic cancer requires an efficient drug 
delivery system that will target the tumour site instead of the normal tissues (Dimou et 
al 2012). In order to develop more efficient and efficacious therapies for pancreatic 
cancer, there are two main considerations; these are tumour-specific molecular 
targets and advanced drug-delivery systems. These improvements would enable drugs 
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to be delivered specifically to tumour cells thus preventing the widespread systemic 
toxicity experienced with existing chemotherapies. Additionally, sustaining drugs 
within the therapeutic window over longer durations should lead to more effective 
treatments (Duncan 2006). 
It is argued that the ability of low-molecular-weight drug molecules to stop tumour cell 
progression devoid of causing harm has been problematic in reality, most especially in 
cases of gastrointestinal, breast, lung and prostate cancers. The cause of this challenge 
is recognised to be as a result of ineffective pre-clinical models, non-existence of a 
specific drug in the clinical situation and the acquired difficulty of drug resistance. 
However, over the past decade or so increased knowledge base and interdisciplinary 
studies have led to developments within cancer therapy in the form of nano-based 
drug-delivery systems (Duncan 2006). This project hopes to design and fabricate novel 
drug delivery systems for pancreatic cancer therapy. 
Generally, the foremost chemotherapeutic agents used for the therapy of pancreatic 
cancer are gemcitabine, 5-fluorouracil and the nucleotide analogues. Despite 
therapeutic interventions by researchers, the condition continues to resurface thus 
propelling the design of novel therapeutics for the treatment of cancer (David et al 
2015).  
Yang reported that liposomal gemcitabine is established as the recognized therapy for 
advanced pancreatic cancer which related to clinical advantages (Yang et al 2011). 
Graeser and colleagues designed a newly established liposomal formulation of 
gemcitabine GemLip, 36 nm; 47% entrapment in order to preserve the drug and to 
ensure passive tumour targeting. This GemLip was established in order to improve the 
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pharmacodynamics and pharmacokinetics compared with traditional gemcitabine, and 
demonstrated superior anti-tumoral action in orthotropic mouse models at much 
lower concentrations than free gemcitabine, and is powerfully active regarding 
metastases. The improved in vivo effectiveness of GemLip is associated with its 
sustained release and passive tumour targeting. Other liposomal formulations in 
preclinical stages as delivery systems for pancreatic cancer consist of clinically used 
chemotherapeutic elements such as adriamycin, 5-fluorouracil (5-FU) and irinotecan. 
The similar success could be achieved utilising integrin-binding peptide conjugated 
liposomes. The use of integrin is more active on the angiogenic endothelial cells. 5-FU 
and doxorubicin loaded in PEGylated cationic liposomes, which demonstrated an 
importantly better relation with human endothelial versus cells of pancreatic cancer, is 
designed. (Khan et al 2015) In vitro studies demonstrated improved development of 5-
FU and inhibitory properties of doxorubicin. The propensity of PEGylated cationic 
liposomes to gather alongside vessels in pancreatic tumour in disparity to the tumour 
interstitial shows that liposomes could be utilized to transmit chemotherapeutic 
elements to tumour vasculature. 
 
Figure 1-2: Pancreatic cancer and its development  
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1.1.1.2   Types of pancreatic cancer 
There are several factors causing pancreatic cancer, these include genetic syndromes, 
where the incidence of pancreatic cancer is 2% in adults and 10% in people aged 70 
years or above (Bardeesy et al. 2014). There are many types of pancreatic cancer 
depending on the position of the pancreatic tumour. Therefore, pancreatic cancers are 
arranged based on the origin of the tumour into exocrine pancreatic tumour that 
ledge for approximately 95% of all pancreatic cancers where the tumour strikes the 
exocrine part of the pancreas and the endocrine pancreatic tumour which is 
inculpated in the endocrine part of the organ. Moreover, a range of rare pancreatic 
malignancies are examined, like; adenosquamous carcinoma and mucinous non-cystic 
carcinoma (Heining et al 2018). 
1.1.1.2.1 Adenosquamous carcinoma 
This is a carcinoma of the pancreas is a rare form of ductal adenocarcinoma that shows 
glandular and squamous differentiation Figure 1-3. Even though squamous 
characteristics in some cases predominate, careful examination almost always reveals 
a glandular component. These carcinomas often occur in patients who have received 
radiation or chemotherapy and This squamous component comprise at least 30% of 
the neoplasm. Due to relatively poor prognosis associated with this rare tumour, 
recognition is important (Weidner, 2009). 
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Figure 1-3: H&E staining with the typical trabecular pattern of a well-differentiated 
pNEN (Hruban & Wilentz. 2009) 
 
The pancreas consists of three parts, the head, the body and the tail. The most 
common type is the one formed at the start of the head of the pancreas which is 
called pancreatic ductal adenocarcinoma (PDAC) (Hruban & Wilentz. 2009). Pancreatic 
cancer can be classified into four stages depending on the size of the tumour (Cancer 
research UK,2016).  
1.1.1.3 Clinical presentation 
Clinical display depends on the position of tumour and disease phase. Obstructive 
jaundice and weight loss are the most familiar presenting features of tumours in the 
head of the pancreas. Abdominal pain and weight loss are the most familiar presenting 
features of tumours emergent in the body and tail. Affliction is an essential clinical 
symptom stated as a deep, dull and aching pain originating from the upper abdomen 
and scattering to the back. Pancreatic cancer can cause alternative signs and 
symptoms such as asthenia, anorexia, hyperglycemia, abnormal liver function, 
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panniculitis and superficial venous thrombosis. Locally progressed tumours can cause 
gastric outlet obstruction, duodenal obstruction and rarely gastrointestinal bleeding 
(Hidalgo, 2010). 
1.1.1.4    Treatment of pancreatic cancer 
Pancreatic cancer can be classified as endocrine and exocrine neoplasm. Exocrine 
tumours constitute more than 95 % of all tumours diagnosed. The percentage of the 
endocrine type is very low at about 9 %. 
 Pancreaticoduodenectomy is the most effective form of treatment for pancreatic 
cancer in the early stage of the disease (where the disease has not spread to others 
parts of the pancreas) (Ferrone et al. 2012 & Shrikhande et al. 2007). Radiotherapy can 
also be used in the treatment of cancerous cells. Radiotherapy is a form of a curative 
treatment that uses high energy x-rays to target and destroy tumours and cancerous 
cells. Radiotherapy works along with chemotherapy which has side effect by targeting 
normal cells too, but usually, cancerous cells cannot repair themselves, unlike some 
normal cells. It is the less suggested and used cure than a surgery or even 
chemotherapy in treating pancreatic cancer. 
The Radiotherapy can be given either: 
-Before surgery to ease the fact to remove the tumour or the Neo-Adjuvant after 
shrinking it. 
-After surgery, to make the tumour or the Neo-adjuvant small with less to no chance 
of coming back. 
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However, the fact that the Neo-adjuvant and adjuvant radiotherapy are still subject to 
experimental treatment, and aligning with chemotherapy to withdraw the cancer and 
make it under control is called chemo radiation (Shrikhande et al. 2007). 
In addition to that, the radiotherapy has side effects and the common knows ones are 
tiredness and bones pain. To minimize these effects, the treatment is split into twenty 
fractions given four times a week for example, the dosage of the radiotherapy give 
shorten the treatment sequences as well as relieving the symptoms of bone pain 
(Ferrone et al. 2012). 
Targeting the cancerous cells or tumours by the radiotherapy requires a complex 
computer model, so the focus of targeting the tumour can be successful and 
improved. Moreover, Stereotactic radiotherapy which is a nonsurgical radiation 
therapy method used to target tumours with a high dosage although, it has the same 
side effects but in a shorter time. 
 Also, Cyberknife is another example of this type of therapy but with big potentials, 
lesser side effects even though there is no proof that it is more effective than the 
traditional treatment͘ IGRT which stand for ͞image guided radiotherapy͟ is for all 
types of radiotherapy for pancreatic cancer, and it requires taking images before and 
sometimes during treatments to help the delivery of an accurate delivery of the 
pancreatic cancer action (Oxford University Press. 2015). 
 Chemotherapy is another treatment option which involves using chemical substances 
to prevent growth of cancer cells (Avendano et al. 2015). Chemotherapy of cancerous 
tissues or tumours is used to curtail or shrink their size/volume.  
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1.1.1.5  Metastasis of  evolution pancreatic cancer    
Depending on the site of tumour, pancreatic cancer cells are classified into four stages  
A. Stage 1: The damage is found only in the pancreas. 
B. Stage 2: The disease develops to other parts closed to the pancreas such as the 
lymph nodes.  
C. Stage 3:  The disease spread to others parts, such as the spleen, abdomen, or large 
intestine.   
D. Stage 4: This is an advanced stage of the disease. The disease spread to other parts 
of the body such as the lungs, the liver or stomach lining (Cancer research. 2017). 
 
As expected, the chance of patient survival is highly dependant on stage at diagnosis. 
With those patients diagnosed with Stage 4 pancreatic cancer having a very slim 
chance of survival. 
1.1.2 Nanomedicine 
The use of nanomedicine is at the cutting edge of modern healthcare and represents a 
promising approach for targeted drug delivery and improved therapeutic efficacy 
(Miragol et al. 2018) Nanoparticles (NPs) is very small particulates in the 1 x 10-9 m 
range. NPs have the ability to inter relate with biological molecules both inside the 
cells and on the surface due to their size. This can help transform cancer diagnosis and 
treatment (Malekigorji, Curtis & Hoskins 2014, Soppimath et al. 2001 and Mccarroll et 
al. 2014). NPs possess multiple advantages over traditional delivery systems. These 
include decreased dosage requirements due to more effective absorption/penetration 
arising from increased solubility / bioavailability. Additionally, NPs result in reduced 
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side-effects, protection of drugs against premature metabolism or degradation hence 
improving drug stability. Furthermore, in cancer treatment the nanoparticles can 
undergo passive diffusion by an effect referred to as the Enhanced Permeability and 
Retention effect (EPR). EPR is experienced when the vasculature of cancerous tissue is 
mal-formed due to its rapid proliferation and nano-sized molecules possess the ability 
to permeate through tiny pores in the capillaries resulting in localised tumour 
accumulation. The poor lymphatic drainage of tumour tissues means the nanoparticles 
cannot escape and this results in effect targeting. (Liu, Miyosh , Nakamura. 2007 
&Mccarroll et al. 2014). 
Another main advantage of nanotechnologies specifically polymeric nanoparticles is 
their ease of functionalization Figure 1-4 (Srinivasan et al. 2015) . Their large surface 
area to volume ratio, dense surface and functional groups results in multiple sites for 
modification or addition of actively targeting moieties or proteins. Biocompatible and 
biodegradable monomers are used in polymers to ensure only non-harmful molecules 
like nitrogen, hydrogen and water is excreted from the body after the release of the 
encapsulated drug (Wissing et al.  2004 in Parveen & Sahoo (2008); Torchilin 2005 in 
Parveen & Sahoo. 2008).  
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Figure 1-4: Schematic diagram representing the mode of action of targeted 
multifunctional nanoparticle (NP) (Srinivasan et al. 2015)  
 
The use of nanoparticles in cancer therapy has been consistently shown to be more 
effective in preclinical studies compared to conventional therapies. Additionally, new 
advances have shown inclusion of imaging agents into the intrinsic structure of the 
nanoparticles enabling dual diagnosis and treatment in one platform (Liu, Miyosh & 
Nakamur. 2007. This suggests that nanoparticles have the ability to act as cellular 
probes for both diagnostic (imaging) and novel intravascular and therapeutic purposes 
(drug/gene delivery) and this is critical in modern medicine (Liu, Miyosh & Nakamura. 
2007).  In the aforementioned study, they reported the successful preparation of 
hollow mesoporous silica nanocapsules involving very tiny shells in the range of 3ʹ10 
nm. This ensured more than 70% ratio of the hollow core to nanocapsules, was 
encapsulated to achieve high drug concentrations. They used fluorescein 
isothiocyanate (FITC) as a model drug and looked at the loading and release in vitro. 
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The data showed that FITC in silica Nano capsules is released at a very slow space than 
free FITC.  The FITC release went up at 1.5 h ( Miyosh & Nakamura. 2007). 
Predominantly NPs are characterized by high solubility in water, so it can be used as a 
means of transport for insoluble drugs thus avoiding toxic solvents ʹ although this is 
not possible on the metallic nanoparticles which require polymeric stabilisation 
themselves (Srinivasan et al. 2015).  Nanoparticles have the ability to penetrate minor 
capillaries and can be taken up by cells, which ensures drugs effectively accumulate at 
targeting locations. A continued and controlled discharge of drugs at target locations 
over a period of time is conceivable.  Several nanosystems developed in this regard 
including micelles, liposomes polymeric nanoparticles of poly(D,L-lactide-coglycolide) 
(PLGA), silica nanoparticles and dendrimers, ( Miyosh & Nakamura .2007).  
However, little is known to this date on the overall toxicity of nanoparticulates over 
long time periods when administered to the body. This is due to the relatively novel 
nature of the technology and the lack of little or no regulation.  It is important to 
consider some downsides of this technology.  Studies have shown that there is lack of 
enzymes which are capable of degrading the polymeric materials in vivo, hence, 
accumulation inside patients over long therapeutic regimes may result in localised or 
systemic toxicity (Lee et al. 2015).  It is also noted that the high cost of production for 
some of the nanotechnologies especially liposomes is a serious issue for consideration 
in addition to the fact that it not appropriate for room temperature storage which 
might allow drug leakage owing to the unpredictability of phospholipids.  Moreover, it 
permits reasonably small drug loading, drug leaking throughout storage and great 
water content of dispersions (70ʹ99.9%) are said to characterise solid lipid 
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nanoparticles. It is important to note that the word nanotechnology relates to any 
particulate on the nanoscale which includes metals, biological molecules, polymers 
and other organic and inorganic substances. In the case of polymers, as long as the 
appropriate toxicological studies are performed in pre-clinical testing the systems 
should be valid for clinical application. It is clear from the above discussion the 
advantages far outweigh the disadvantage in the cancer therapy therefore the need 
for utilisation of the nanoparticle.  
A study by Maskos and Stauber (2011) showed that there is a difference in the 
individual properties of the particles between the aggregates and agglomerates. Such 
as ionic strength, particle surface studying, solubility in water, size and shape, as well 
as the ability to consequent cellular interaction.  In the aggregates, there are 
heterogeneous molecules and the different ingredients cannot be easily separated 
while in agglomerates, the forces that bind the molecules are the Van der Waals 
(VDW) forces and the surface tension in addition to the electrostatic forces. Key 
aspects previously neglected are aggregation conduct of nanoparticles in the biological 
environment (Maskos & Stauber.2011). Aggregation is a status that can be happen in 
protein-rich and electrolyte environments. Often a protein corona can form between 
the nanoparticle surface and the surrounding proteins ʹ the extent of which is largely 
dependant on nanoparticle surface charge (Casals et al. 2012). 
1.1.3 Drug Solubility  
Solubility is the ability of solid, liquid or gaseous compounds to dissolve in a suitable 
solvent. The solubility of compounds depends on the temperature, pressure and the 
solvent used. Some compounds completely dissolve, like methanol in water while 
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others materials have a poor solubility. Insoluble is a term referring to extremely 
poorly soluble compounds (Gajjar et al. 2012). Also the size and shape of the drug 
molecule affects the solubility of the drug.  
Chemotherapies are often practically insoluble which hinders their clinical translation. 
Therefore, formulation strategies are required in order or allow these drugs to be 
administered in aqueous media and improve their chances in clinical trials. 
 
1.1.4 Polymers for drug delivery 
Polymers are large molecules (macromolecules) generated from smaller molecular 
units. These may exist in different architectures such as linear, randomly branched or 
highly branched in generations. The building blocks of polymers are referred to as 
͚monomers͛ ;Nicholson ϮϬϭϮ, Campbell 2000 and de Ilarduya & Gonzalez-
Aseguinolaza, 2012).  
 The idea of using polymers in the development of therapeutic agents has been the 
focus of many studies in the past decade (Larson & Ghandehari, 2012). The 
interdisciplinary research relating to biomedical sciences and polymer chemistry led to 
the development of polymer-based nanomedicines enabling the diagnosis, 
management and treatment of cancer (Vicent & Duncan 2006). Cancer is said to be the 
third principal source of death in developed countries (after heart disease and stroke) 
and/or modern societies and second (after heart disease) in United State of America 
(Malekigorji, Curtis & Hoskins 2014, de Ilarduya 2012 & Liu, Miyosh & Nakamura 
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2007). It is fast growing to the deadliest disease in the world (Shroff & Vidyasgar 2013 
& Lee, Loo, Traini and Young, 2015).  
For polymers to be clinically relevant, the key aspects are that the polymer is water-
soluble, non-immunogenic, non-toxic and safe at all stages of the delivery process 
including safe excretion (Schmaljohann 2006 &Yan, Zhuo & Zheng 2007). The term of 
polymer therapeutics is adopted to include different families of polymer-drug 
conjugates, polymer pro-drugs with polymer- associated delivery systems (Vicent and 
Duncan 2006 & Yan, Zhuo & Zheng ϮϬϬϭͿ͘ Polymers are employed to convey ͚the drug 
to targeted site in controlled manner, achieving the high-therapeutic efficacy͛ 
(Paramjot et al. 2015).  
1.1.5 Types of polymeric constructs      
Polymer constructs have shown great potential in cancer therapy.  This can be through 
drug encapsulation, site-specific targeting or stimuli-responsive release of compounds. 
The family of ͚Polymer therapeutic͛ has been described to include all the constructs 
utilizing ͚water-soluble polymers͛ as constituents in the process of the design͘ These 
include polymer drug-conjugates, polymeric drugs, polymer-protein conjugates and 
polymeric micelles (Duncan et al 2006) & (Prabhu et al. 2015). 
Platforms for polymeric nanoparticle are considered by their physicochemical 
composition, including polymeric micelle, nanoshell, polymerosome, solid polymeric 
nanoparticle, polymer-drug conjugates and dendrimer (Alexis et al. 2008:506).  
1.1.5.1 Polymer–drug conjugates 
Polymer-drug conjugates are systems where drug molecules are chemically conjugated 
onto long chain polymers via covalent linkages. At the moment there are more than 14 
17 
 
polymer-drug conjugates that have made it through the rigorous clinical evaluation, 
these are based on poly(glutamic acid) (PGA)-paclitaxel conjugates (CT-2303, OPAXIO®, 
initially known as Xyotax®) (Greco & Vicent 2009). Polymer-drug conjugates hold the 
potential to protect the drug from early degradation, an inhibit drug from prematurely 
releasing with the biological setting and improve the absorption of the drugs into the 
tissues (by means of improved permeability and retaining effected or active targeting). 
Drugs molecules possess the ability to be conjugated to water-soluble polymers or 
amphiphilic block copolymers through biodegradable ester or amide bonds. This 
increases water solubility, decrease removal from the reticulum endoplasmic system 
(RES), offer an extended circulation time, enhance pharmacokinetics and stimulate 
tumour targeting through improved permeability and retaining capability. In 
comparison, with polymeric nanoparticles, polymerʹdrug conjugates have the benefits 
of increased drug loading, improved stability and enhanced control over the drug 
release kinetics. Additionally, it is possible to conjugate the drugs onto the polymer 
structure via ͚smart͛ or stimuli responsive linkers enabling drug release on demand 
(Paramjot et al. 2015 & Vicent 2007). 
1.1.5.2 Amphiphilic polymers 
Amphiphilic polymers consist of both hydrophilic and hydrophobic moieties 
(Hoskins,2010). Amphiphilic polymers over huge improvements over the low molecular 
weight surfactants in the process of drug solubilisation (Zhang & Kim 2015 &  Santos et 
al. 2016Ϳ͘ These surfactants are significant in recent drug delivery as they help in ͚the 
control of drug uptake and release rate and minimization of drug degradation and 
toxicity͛ ;Santos et al. 2016). The main parameters for amphiphilic polymer optimisation 
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in drug delivery are the type of hydrophilic/hydrophobic subunits and their relative 
sizes; as well as the ratio of hydrophilicity to hydrophobicity (Leser &Garli 2001).  
Once inside an aqueous environment these systems spontaneously aggregate into 
core-shell structures due to a reduction in Gibbs free energy. The hydrophobic core of 
the nano aggregates has been exploited in numerous studies for the incorporation and 
hence solubilisation of poorly soluble drugs. Micelles forming colloidal dispersions 
from amphiphilic molecules can be in the range of ~20 nm-200 nm in diameter. The 
small size still results in increased circulation time, as well as tumour tissue 
penetration after extravasation when compared to larger macromolecular systems 
such as liposomes (Blanco et al. 2009 cited in Khan 2010). Degim and Celebi (2007 
cited Khan ϮϬϭϬ͗ϲϬͿ state that ͚the hydrophobic core found within micelles allows for 
the encapsulation and delivery of hydrophobic drugs which many can be used for 
chemotherapy. The solubilisation of hydrophobic drugs further eases the danger of 
drug aggregation in the process of intravenous administration and possible embolism 
formation͛ ;Degim &Celebi, 2007 cited Khan 2010:60). Aliabadi indicated that the 
͚polymeric micelles are nanoscopic coreͬshell structures formed through self-assembly 
of amphiphilic block copolymers͛ (Aliabadi et al. 2008:619). 
Larson and Ghandehari (2012) also indicate that micelles are colloidal particles which 
have a size of nearly 5-150 nm comprising self-assembled collections of amphiphilic 
molecules or surfactants. Lower concentrations of amphiphiles in aqueous media, 
occur as unimers in solution but as the concentration was improved, thermodynamic 
processes allows the formation of aggregates, which sequester hydrophobic drives 
into corelike structures enclosed by a hydrophilic corona or shell. The level of 
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concentration the aggregate occurs is usually known as the critical aggregation 
concentration (CAC). Amphiphilic molecules (in the form of unimers or micelles) have 
the potential to increase drug permeability through physiologic obstacles, defend the 
drug from cases of inactivation by its biologic backgrounds, reduce its toxicity, 
decrease the occurrence and robust of side effects, and reverse MDR (Garrec, Ranger 
& Leroux 2004).  
Amphiphilic polymer can exist in several architectures. The most popular in drug 
solubilisation being the block copolymers and graft polymers.  
1.1.5.3 Block copolymer 
Block copolymers systems consisting of a hydrophobic segment attached to a 
hydrophilic segment in a linear fashion as show in Figure 1-5. These can be composed 
of two, three, four or multiple segments.  
 
Figure 1-5: Schematic representation of the varied architectures of block copolymers                        
 
It has been demonstrated these nano-containers have the capability to encapsulate 
poorly soluble drugs, within their lipophilic core, via hydrophobic-hydrophobic 
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interactions. On their in vivo journey, the nano-carriers protect the drug payload from 
enzymatic degradation, leading to an efficient delivery to the target site. The most of 
the self-assembling polymers comprise of block copolymers are shaped largely 
through copolymerisation of hydrophobic and hydrophilic monomers (Hoskins et al. 
2010). 
Drugs loading is achieved by encapsulation of the drugs into the hydrophobic core 
when in the aqueous phase, additionally more sophisticated methods of encapsulation 
include adjusting surface elements of NPs, trapping drugs through chemical cross-
linking, etc. A significant amount of polymeric NPs is in the preclinical stage for the 
transmission of cancer therapeutics to the unlimited likelihood for targeted delivery. 
Most especially in recent times the interest of engaging synthetic polymers like 
poly(ethylene glycol) (PEG), poly(lactide) (PLA), and poly(D,L-lactideʹco-glycolide) 
(PLGA) is growing (Shroff & Vidyasagar (2013). 
Numerous drugs have experienced great challenge in the ability to target their specific 
site of therapeutic need as a result of bloodʹbrain barrier in the instance of central 
nervous system cancers. Drug-loaded NPs are capable of overcoming this barrier and 
have demonstrated to significantly improve therapeutic required that the 
concentrations of anticancer drugs in brain tumours (Koziara et al. 2004 in Parveen & 
Sahoo (2008); Steiniger et al. 2004 in Parveen & Sahoo (2008). Significantly, P-
glycoprotein (P-gp)-associated multi-drug resistance is an added challenge that leads 
to the resistance of tumours to anticancer agents. The small size of NPs and suitable 
surface coating might have the capability to resolve the challenge of drug resistance 
(Feng &Chien 2003 in Parveen & Sahoo 2008). 
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Pluronics were the first commercially available amphiphilic polymers for universal drug 
solubilisation. Pluronics are block copolymers comprised of poly(ethyleneoxide) and 
poly(propylene oxide). Pluronics have been shown to enhance the oral bioavailability 
of the numerous drugs because of their capability to prevent the efflux carriers found 
on intestinal epithelial cells (Aliabadi 2008). Johnson et al. (2002 cited in Aliabadi, 
2008) in their study made use of the intestinal uptake of digoxin and verapamil from 
rat jejunal tissue using Pluronic® P85. and it revealed that Pluronic® P85 inhibited both 
drug efflux and drug metabolism. This kind of inhibition was made possible as a result 
of ͚reduced substrate uptake, direct inhibition of the cytochrome PϰϱϬ ϯAϰ enzyme or 
P-gp, or an indirect effect on the normal function and the permeability of cells͛ 
;Aliabadi ϮϬϬϴ͗ϲϮϮͿ͘ Earlier studies discovered an upsurge ͚in the oral bioavailability of 
amikacin and tobramycin antimicrobials that are P-gp substrates, in the presence of 
Pluronic® CRL-ϭϲϬϱ in mice͛ ;Aliabadi, 2008:622). 
1.1.5.4 Graft polymers 
Graft polymers are composed of a water soluble homopolymer backbone with 
hydrophobic groups randomly grafted on Figure 1-6 (Nicholson, 2012). In aqueous 
environments the hydrophobic groups shield themselves forming core-shell structures 
which like block copolymers are capable of solubilising poorly soluble drugs.       
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Figure 1-6: Schematic representation of a graft polymer 
  
Usually, poly(allylamine), poly(ethylenimine) and chitosan backbones have been 
utilized in the formation of these amphiphiles. Studies have shown the potential of 
poly(allylamine) (PAA) grafted with cholesteryl and dansyl moieties to perform as 
universal hydrophobic drug solubilizers. Typical drugs in this instance include 11β-
11,17,21-trihydroxypregna-1, 2,6-diisopropylphenol (propofol), 4-diene-3, 20-dione 
(prednisolone) and ;ϮS,ϲ͛RͿ-7-chloro-Ϯ͛,ϰ,ϲ-trimethoxy-ϲ͛-methyl-ϯH,ϰ͛H-spiro[1-
benzofuran-Ϯ,ϭ͛-cyclohex[2]ene]-ϯ,ϰ͛-dione (griseofulvin) (Barnet et al. 2014). 
The major advantage of graft polymers over block copolymers is their ability not only 
to aggregate through intermolecular aggregation but also through intramolecular 
aggregation. This results in much lower CAC values which infers increased stability 
upon dilution and lower excipient: drug ratios making the overall system more 
efficient and cost effective. 
In structural suitability relating to drug polymer interfaces (Gu et al. 2011) 
demonstrated that the chemical structure of the hydrophobic pendant group of the 
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amphiphilic graft copolymers has considerable impact of the solubilisation of poorly 
water-soluble drugs. Gu et al. 2011 indicated that ͚the pendant group of graft 
copolymers could be the only hydrophobic moiety that will form the hydrophobic 
micro domains and contribute to the major interaction with the hydrophobic drug 
molecules͛͘ Gu et al. Indicated that studies have shown that the supramolecular 
structures shaped through amphiphilic graft copolymers can change from polymeric 
micelle to solid nanoparticle resulting in an increase of hydrophobicity (Wang et al. 
2004; Qu et al. 2008)& (Gu et al. 2011). 
Hoskins et al. showed the potential of an aqueous polymer-drug formulation 
comprising of poly(allylamine)-cholestrol as drug carriers for pancreatic cancer 
therapy. The aggregates formed possessed a mean hydrodynamic size of 138 nm 
(Hoskins et al. 2010).  
They formulated novel anticancer drug Bisnaphthalimidopropyldiaminooctane. The 
drug aqueous solubility was increased from negligible concentration to 0.3 mgmLʹ1. 
The new polymer- drug formulation exhibited effectiveness in vitro and in vivo 
anticancer activity, whilst CH5-PAA polymer only could not show cytotoxicity, 
therefore the in vivo results showed that the CH5-PAA in isolation did not possess any 
anti-proliferate effect .  However, the formulation showed related tumour reduction 
efficacy as gemcitabine does, therefore this formulation has the potential to function 
effectively in pancreatic cancer therapy (Hoskins et al.2010:1).  A vital method in drug 
delivery strategy is related drugs can be targeted to precise organs, tissues or cells. In 
this process, the toxic side effects of the drugs in question is inhibited and the 
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circulation of drugs are altered after injection, to enhance the uselessness toward 
malignant cells, and decrease the drug dose (Yan et al, 2007). 
 
1.1.5.5 Star shaped polymers 
Star shaped polymers have been reported for drug delivery for over a decade now 
because of their solution and solid-state properties as in Figure 1-7. The key 
characteristics of star-shaped polymers include it solid structure (for example radius of 
gyration and hydrodynamic volume) and a considerable concentration of function 
terminal groups, giving them high solubility in common solvents, melt viscosities and 
lower solution, and modified thermal properties. 
 
Figure 1-7: Schematic representation of star shaped polymers (Iatridi &T sitsilianis, 
2011) 
 
Rozga-Wijas successfully prepared two novel silsesqui-oxane based initiators for ring 
opening polymerization of L,L-dilactide. They were synthe-sized by thiol-ene addition 
of 6-mercapto-1-hexanol to mono- and octavinylsilsesquioxanes (Rozga-
Wijas,2015:4420). The mono- and multihydroxy silsesquioxane initiators could be 
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effective used for the synthesis of tailor-made biodegradable inorgano-organic star 
shape and linear polymers. The structure both of initiators and the respective polymer 
composites was proven by mass spectrometric analysis and systematic 1H, 13C and 29Si 
NMR. Also, (Hart et al. 2014:8-ϵͿ In this work reported that ͚both the comb and star 
copolymers exhibited significant degree of inter-lamellar bridging, as exemplified for 
this systems at the weight fraction Ϭ͘ϰϵ and χN с ϭϳϱx͛͘ ;Fonseca et al. 2015) 
reportedly synthesized a star-shaped PCL which was again prolonged with a terminal 
block of poly(ethyl ethylene phosphate) (PEEP) to achieve a PCL-PEEP star-shaped 
copolymer. The copolymer demonstrated an effective capability to form micelles in 
aqueous solutions and was utilized to encapsulate DOX as show in Figure 1-8. The 
release in vitro examination demonstrated that DOX was delivered in a pH-dependent 
way, which was faster at pH = 5.4 than at physiological pH. The DOX-loaded micelles 
showed an improved cytotoxicity for both drug resistant human breast cancer cell 
positions (MCF-7) and drug-sensitive. The examination of the cellular absorption of the 
DOX-loaded micelles was ensured by the ways of confocal microscopy. An efficient 
fluorescence in the cytoplasm involving the cells demonstrates that the micelles were 
adopted via endocytosis. Significantly, the drug-resistant cells demonstrated greater 
cellular absorption than their drug-sensitive colleagues (Fonseca et al. 2015). 
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Figure 1-8: Structure of the PCL-PEEP star-shaped copolymer and micelles͛ 
development (Fonseca (2015 :11)) 
 
Boyer et al. reported that they developed and made cationic biodegradable star 
polymers utilizing DMAEMA ( N,NͲdimethyl aminoethyl methactylate)  as the monomer 
and reversible addition-fragmentation chain transfer RAFT polymerization to achieve 
an organised star polymers which are stable in water and soluble (Boyer et al. 2013). 
The polymers consisted advance amino collections alongside the polymer arms, which 
permitted for quick and effective self-assembly with siRNA. In this instance the star 
polymerоsiRNA complexes were smaller and same in size and were nontoxic in both 
lung cancer cells and pancreatic. Also, the star polymer capably delivered siRNA to 
quiet target genes in both cancer cell types. Moreover, the star polymer was capable 
of transmitting good siRNA and silences its target gene in an in vivo mouse tumour 
ideal.  
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1.1.5.6 Dendrimers 
Nicolson stated that dendrimers are macromolecules consisting of many branches 
developed from one main point or centre Figure 1-9 (Nicolson ,2012). They are said to 
greatly mono disperse (characteristically polydispersities in the order of 1.02-1.04, it is 
however in some cases lower than 1.001). (De Ilarduya & Gonzalez-Aseguinolaza 
.2012) also describes dendrimers as branches macromolecules with tree shapes but 
variety of dendrimers can emerge during polymerisation process depending on its core 
structure. The branches emanating from the core of the molecule are nearly identical 
length thereby developing a globular morphology. Different dendrimers molecules 
consist of three different zones; they are the core, the branches and the end-groups 
(Nicolson, 2012).     
Dendrimers have unique properties that include the capability to capture minor 
molecules in their central region and very little intrinsic viscosities in solution. These 
properties need molecules to have attained a specific size but not all molecules 
branching from central point are adequately huge to advance these distinctive 
properties of real dendrimers. Those branched molecules below this vital size are 
referred to as dendrons and are the comparable in dendrimer chemistry oligomers in 
polymer chemistry (Nicolson, 2012).         
According to (Nicolson, 2012) dendrimers are often created by one of the two 
synthetic methods. The methods are the following; 
I. Growing resurgent from the central point, referred to as the divergent 
method. In this approach the potential dendrimer central point is made 
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first and the subsequent branches developed out of it by use of suitable 
methods of synthesis.   
II. Growing from the end-groups inward, referred to as the convergent 
method.  In this approach the potential periphery of the molecule is 
developed first, subsequently the synthesis continues inwards in 
appropriate manner till the central point is finished.    
In talking about the shapes and confirmation of dendrimer as demonstrated in   
(Nicolson,2012) states that they can either folded be in or at the external part of the 
dendrimer globule, which is referred to as the periphery. The shape or form it takes is 
influenced by the degree of strictness in the branching process.  True dendrimers tend 
to be a globular structure and fairly rigid in nature whilst the interior appears to empty 
enabling it to accommodate guest molecules and sometimes nanoparticles (Nicolson, 
2012).  
 
Figure 1-9: Schematic representation of dendrimer structure (Science Photo Library / 
Alamy Stock Photo,2016)  
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Dendrimers solubilise drugs in a different manner to the other polymeric systems. The 
drug molecules can be trapped in the inner hydrophobic core in polymeric micelles, 
whereas the surface shell is hydrophilic and soluble in aqueous media.  
The family of dendrimers examine the most by researchers for drug delivery are the 
poly(amidoamine) (PAMAM) dendrimers. These PAMAM dendrimers are 
biocompatible, water-soluble, non-immunogenic and possess terminal- modifiable 
amine functional groups for holding various targeting or guest molecules together. 
Pancreatic cancer researchers who are in search of treatment have demonstrated that 
drug delivery and tumour specific targeting which has the potential to prevent side 
effects is essential. Dendrimers show the potential for the delivery of platinum 
compounds in this process, making it a significant polymer in the treatment of 
pancreatic cancer (Yang et al. 2011 & Kesharwani et al. 2015). Current improvements 
in polymer and dendrimer chemistry have given a different class of molecules referred 
to as dendronized polymers, these are linear polymers that accept dendrons at each 
repeat unit. The attitude of these polymers differs from that of linear polymers and 
permit drug delivery benefits as a result of their improved circulation time. Additional 
method has been to synthesize the drug to the dendrimers in order to allow 
incorporating of a degradable relation that can further be used to control the release 
of the drug (Singh & Lillard Jr, 2012). 
Lee et al. 2006 reported the careful design of size and molecular architecture was 
done which ensured that DOX was conjugated to a biodegradable dendrimer with 
enhanced blood circulation time. In this instance, the DOX-dendrimer controlled drug-
loading using several attachment sites, solubility through PEGylation, and drug release 
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through the utilization of pH-sensitive hydrazone dendrimer linkages as in Figure 1-10 
(Lee et al. 2006 cited in Singh & Lillard Jr ,2012)͘ At the same instance in culture, ͚DOX-
dendrimers were хϭϬ times less toxic than free DOX toward colon carcinoma cells͛͘ 
Upon intravenous administration to tumour possessing mice, tumour absorption of 
DOX-dendrimers were nine-fold greater than intravenous free DOX and permitted 
comprehensive tumour recession and 100% existence of the mice afterwards 60 days. 
 
Figure 1-10: The conjugate of Dox to a biodegradable dendrimer (Wang et al. 2012) 
 
Also, (Kesharwani et al. 2015) in their study used dendrimer related drug-delivery 
approach utilizing HA as targeting ligands to provide 3, 4-difluorobenzylidene curcumin 
(CDF) precisely to cells affected by pancreatic cancer. Also, a reduction of the cationic 
surface charge of the noble PAMAM was achieved thereby improving the possibility of 
its transformation at the clinical level. 
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1.1.5.7 Stimuli response polymers (smart polymers) 
Stimuli responsive or ͚smart͛ polymers Figure 1-11 possess unique properties whereby 
they undergo change (either chemical or physical) upon external or internal stimuli 
(Schmaljohann 2006). These properties can be exploited in drug delivery as a triggered 
release mechanism. These types of polymers can again be categorized depending on 
the stimuli they react to as: temperature, pH, ionic strength, light, electric and 
magnetic field sensitive. Some polymers react to a mixture of two or more stimuli 
(Meng& Li, 2013). (Gil & Hudson, 2004) Whilst categorizing the diverse stimuli use to 
moderate the response of polymer systems into two physical (such as cross-liked 
hydrogels, reversible hydrogels, modified interfaces, micelles and so on) or chemical 
stimuli (such as pH, ionic factors, chemical agents and so on), they state further that 
several names like intelligent, stimuli responsive, smart or environmental sensitive 
polymers have used to describe polymers stimuli response. 
 
Figure 1-11: Cataloguing of stimuli responsive polymers. (Ganesh,2014) 
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Smart polymers have been designed to contain varieties of properties, including the its 
potential to react to changes occurring in the environmental stimuli for instance pH, 
ionic strength, temperature magnetic including electric fields or sound. This type of 
polymers react through conformational and/or electronic changes is the potential to 
be explored to aid a certain function (for example drug release and so on.) Those 
carriers that react to disparities in pH and temperature have created flexibility in drug 
delivery (Larson & Ghandehari, 2012).  
In the application of stimuli response polymers in drug delivery it is observed that 
hyalouronic acid hydrogel that experiences photosensitized degradation in the 
existence of methylene blue permits the likely application of observable light-
responsive hydrogels for temporal drug delivery can be largely grounded on the 
reaction of cross. Additional activation mechanism can be used of infrared light which 
elicits a response in hydrogels in the absence of chromophores. The key advantage of 
this method is the high infrared light absorbency of water which is key in this process. 
When hydrogels without chromophores are irradiated by CO2 infrared laser the 
volume phase transition along with gel bending towards the laser beam is observed, 
while the relaxation of the gel to its original form after irradiation was terminated is 
followed (James, John, Alex & Anoop 2014). 
 
1.1.6 Magnetomicelles 
Magnetomicelles are a new class of macromolecules comprising of amphiphilic 
polymers with magnetic iron oxide nanoparticles impregnated into their structure. The 
combination of the amphiphilic polymers with Inorganic metallic nanoparticles results 
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in a multifunctional platform image-guided drug delivery.  Barnett et al.  Reported of a 
poly(allylamine)-oxadiazole amphiphilic graft polymer with a gold coated iron oxide 
nanoparticle incorporated into the polymer structure (PAA-Ox5-HNP). The results 
show that once conjugation of metallic HNPs onto the polymer amphiphile structure, 
the drug loading is improved with an associated reduction in the in vitro drug release 
(Barnett et al. 2013).  
Magnetic particles have exclusive characteristics it possible for different medical use. 
The most vital aspect of the magnetic particles is their response to a magnetic force, 
and this characteristic is used in cases of drug targeting and bio-separation as well as 
cell sorting. In recent times magnetic nanoparticles have gained attention as result of 
their ability as contrast agents for magnetic resonance imaging (MRI) and heating 
mediators for cancer treatment (hyperthermia) (Ito et al. 2005). 
(Kim et al. 2008) reported that for the first time running, separately well-dispersed 
thermo-sensitive magnetomicelles with a size of around 18 nm, involving a 
functionalized Fe3O4-OA magnetic core and a thermo-sensitive amphiphilic P(OA-co-
NIPAAm) surface layer, were developed and constructed. The ready designed Fe3O4-
OA-g-P(OA-co-NIPAAm) magnetomicelles demonstrated temperature sensitivity with a 
LCST at 30.9 මC, as well as good magnetic character Figure 1-12. 
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Figure 1-12: Schematic explanation of the nano-sized thermo-sensitive magnetic 
micelle for drug delivery 
 
Controlled drug-release data showed that the Fe3O4-OA-g-P(OA-co-NIPAAm) 
magnetomicelles have the greatest possibility as thermo-sensitive drug carriers. Also, 
(Kim et al. 2005) reported that TEM images of the magnetomicelles showed that the 
number of encapsulated particles could be organized rationally by synthetic 
conditions. The magnetic elements of the particles were characterized by 
superconducting quantum interference device  SQUID magnetometry and followed 
the overall Langevin magnetic model for superparamagnetic materials. The micellar 
shells of these particles were functionalized using covalent chemistry that would not 
usually be possible on the magnetic particle surface. The outcome of this has been 
that, this non-covalent method offers a new way to technological usage of 
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hydrophobic magnetic nanomaterials that lack appropriate conjugate surface 
chemistry. 
1.1.7 Research Aim 
The aim of this work is to develop a thermally releasing magnetomicelle preparation 
for pancreatic cancer therapy. 
To fulfil this aim, a novel PAA-oxadiazole graft polymer will be created into which a 
hybrid nanoparticle will be incorporated via dative covalent binding between the thiol 
of the oxadiazole pendant and the gold surface. The polymer will be chemically 
characterized using nuclear magnetic resonance (NMR) and fourier transform infrared 
(FTIR) spectroscopy.  Ability of the polymers to aggregate in aqueous environments 
will be determined using photon correlation spectroscopy and surface tension 
measurement. Ability of the amphiphile to encapsulate hydrophobic drugs will be 
determined using model drugs propofol and griseofulvin and measured using high 
performance liquid chromatography (HPLC). Optimal PAA molecular weight for use as 
a drug delivery vehicle will be identified. 
The organic synthesis will be carried out using established protocols from the 
literature. Structural analysis of the compounds will be carried out using nuclear 
magnetic resonance, Fourier transforms infrared spectroscopy and thin-layer 
chromatography. 
 Hybrid nanoparticle will form the basis for drug incorporation. Two novel doxorubicin 
analogues will be developed as in Figure 1-13.  The organic synthesis will be carried 
out using established protocols from the literature. Structural analysis of the 
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compounds will be carried out using nuclear magnetic resonance, Fourier transforms 
infrared spectroscopy, 13C NMR spectrum and thin-layer chromatography. These will 
be capable of electrostatic attachment onto the hybrid nanoparticle within the micelle 
core of the nano-aggregate formed. It is hypothesised that upon laser irradiation, that 
the thermal energy required to break the electrostatic binding will be achieved 
resulting in localised drug release. This will be tested in vitro. Finally, in vitro evaluation 
of the system will be carried out in order to determine whether the novel heat 
triggered drug delivery will result in improved treatment in pancreatic cancer cell lines. 
 
Figure 1-13: Fabrication of novel doxorubicin analogues for enhanced pancreatic 
cancer therapy 
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CHAPTER TWO 
2 SYNTHESIS, CHARACTERISATION AND OPTIMISATION OF POLYMERIC AMPHIPHILES FOR DRUG DELIVERY 
 
 
 
38 
 
2.1 Introduction 
Amphiphilic polymers have played a key role in the development of drug delivery 
technology by controlling long-term release of therapeutic factors hence stabilising 
doses. Polymeric nano-aggregate can be organised from different variety of 
architectures but of interest to this project are graft polymers and polymeric micelles. 
Graft polymers are composed of a water soluble homopolymer backbone with 
hydrophobic groups randomly grafted on (Nicholson 2012 & Barnett et al. 2013). 
In the process of delivery of drugs to their target site and particularly for a number of 
anticancer drugs polymer micelles have been generally utilised as nano-sized vehicles 
for solubilizing several poorly soluble drugs. In this instance, the solubilization of 
poorly soluble drugs is largely reliant on hydrophobic relations between the drug and 
the micelle core (Kim et al. 2011). 
Amphiphilic polymers consist of a hydrophilic and hydrophobic domain and have been 
generally explored in recent times. The amphiphilic molecules associate through weak 
non-covalent hydrophobic-hydrophobic interactions in aqueous environments 
whereas, the hydrophilic moiety will remain in connection with the aqueous phase 
whilst the hydrophobic moiety will ͚shield͛ themselves, thereby forming a polymeric 
micelle. Amphiphilic polymers form a wide range of structures in aqueous 
environments including vesicles, polymeric micelles, and nanoparticles (Hoskins, 
2010). 
Amphiphilic polymers have the ability to encapsulate hydrophobic anticancer drugs 
inside their polymeric aggregates which spontaneously form in aqueous environments. 
Here, the inner core consists of the hydrophobic pendants surrounded by the 
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hydrophilic outer shell. Furthermore, the hydrophilic corona which forms in vivo can 
increase the polymeric aggregate stability in blood plasma allowing for increased 
circulation time and reduced opsonisation and capture by reticulo-endothelial system. 
Polymeric aggregates are well-known to possess lower critical micelle concentration 
(CAC) compared with the surfactant micelles, recording as low as 10-6 M. All these 
points make polymeric aggregates a model carrier for anticancer drugs and tumour 
targeting as in Figure  2-1 (Neha et al 2013). 
 
Figure  2-1:  Schematic  explaining  the  micellization  of  copolymers  and  drug 
encapsulation  inside  polymeric  micelle  ( Hussein & Youssry, 2018) 
 
Poly(allylamine) has previously been investigated for its use as a drug delivery vehicle 
(Barnett et al. 2013). Poly(allylamine) (PAA) is a positively charged polymer that is to 
some extent non-toxic, making it an excellent model biomaterial to be explored in 
drug delivery. The cross-linked PAA is available clinically as an oral phosphate cover. 
Therefore, modification of PAA to form amphiphilic polymers has been explored for 
biomedical application (Hoskins, 2010). PAA can undergo chemical adjustment via its 
primary amine functional groups enabling grafting of a multitude hydrophobic 
moieties by a simple nucleophilic replacement reaction. Thompson and colleagues 
have reported that varying the hydrophobic groups on the PAA backbone had an 
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important impact on the polymer properties and the self-assemblies formed in the 
aqueous environment. 
However, the effect on aggregation ability and solubilisation potential of varying its 
molecular weight have not been studied. Hence, in this work, we will develop a series 
of amphiphilic PAA polymers modified with hydrophobic pendant group oxadiazole. 
We will vary the molecular weight of the homopolymer backbone whilst maintaining 
5% molar pendant substitution. Oxadiazole has been identified as a promising 
hydrophobic pendant group due to this thiol functionality which can be used to bind 
gold nanoparticulates ʹ a quality which will be required further into this thesis. 
In this work two model hydrophobic drugs will be investigated in order to estimate 
whether the amphiphiles created can be used for drug delivery. These are propofol 
and griseofulvin. 
Propofol (6-diisopropylphenol) Figure 2-2 is used as an intravenous sedative. It was 
discovered in 1977 and approved for use in humans by the food and drug 
administration FDA in 1989. Propofol has not yet been earmarked as a controlled drug 
anywhere in the world except in Korea even though there is the possibility to obtain 
and abuse it (Kim et al. 2015). The chemical formula of propofol is C12H18O with molar 
mass is 178.271 g/mol (Muzi et al.1997). It is a small hydrophobic molecule with is 
currently administered in an oil based formulation. This is problematic because it 
causes pain on injection, hence an aqueous based formulation would be much more 
desirable. 
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Figure 2-2: Chemical structure of propofol, 2,6-diisopropylphenol (C12H18O) M.W 
(178.27 g/mol) 
 
Griseofulvin Figure 2-3 was discovered in 1939 (Stanton ,2001).  It is insoluble in water 
but sparingly soluble in acids such as acetic acid, and in low molecular weight alcohols 
such as methanol and ethanol. Griseofulvin is used in the treatment of many 
dermatological diseases such as delicate skin and nails as well as scalp and the 
systematic treatment of inflamed lesions. The solubility of griseofulvin in water is very 
low (15 pg. /ml at 37 ° C) and this explains the incomplete absorption of the drug after 
oral administration. Several factors affect the absorption of the drug within the body 
such as fat intake, structure, particle size and the rate of dissolution (Lin & 
Symchowicz, 1975). The solubility of griseofulvin is extremely significant for its 
efficacy. Hydrophobicity of drugs is a major problem in clinical applications, thus the 
main focus is to enhance the solubility of the drug by reducing the particle size 
(Jambhrunkar, 2014).  
 
Figure 2-3: Chemical structural of 7-Chloro-Ϯ͛,ϰ,ϲ-trimethoxy-ϲ͛B-methylspiro[ benzo 
furan -Ϯ; ϯHͿJ ͛΀ Ϯϭ cyclohexene ΁ -ϯ,ϰ͛-dione(griseofulvinl) 
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2.2 Aims and Objectives  
The aim of this chapter was to fabricate a PAA based amphiphilic polymer capable of 
aggregate formation and hydrophobic drug solubilisation. The polymer will be 
synthesized and chemically characterized using nuclear magnetic resonance (NMR) 
and fourier transform infrared (FTIR) spectroscopy. Ability of the polymers to 
aggregate in aqueous environments will be determined using photon correlation 
spectroscopy and surface tension measurement. Ability of the amphiphile to 
encapsulate hydrophobic drugs will be determined using model drugs propofol and 
griseofulvin and measured using high performance liquid chromatography (HPLC). 
Optimal PAA molecular weight for use as a drug delivery vehicle will be identified. 
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2.3  Materials and method 
2.3.1  Materials 
The following materials  in Table 2-1  were acquired for purposes of the project. 
Poly(allylamine) (PAA) and  5-(4-chlorophenyl)-1,3,4-oxadiazole -2-thiol.  
Table 2-1 Materials which is used to synthesize the PAA amphiphiles.   
 
Item 
No 
Materials Supplier 
 
1 
Poly(allylamine) Hydrochloride 
ave.Mw 15 kDa, 17.5 kDa, 120 kDa, and 
900 kDa. 
Sigma-Aldrich Co., UK 
 
2 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-
thiol (Oxadiazole) 
Sigma-Aldrich Co., UK 
 
3 Griseofulvin 
 
Alfa Aesar 
4 Propofol 
 
Sigma-Aldrich Co. 
5 
 
Triethylamine. Sigma-Aldrich Co., UK 
6 Sodium hydroxide 
 
Fisher Scientific, UK 
7 Dialysis tubing membranes 
 
Medical International Ltd, UK 
8 Deuterated Methanol 
 
Cambridge Isotope Laboratories Inc., 
USA 
9 Methyl orange Sigma-Aldrich Co., UK 
 
10 Sodium Tetraborate 
 
Sigma-Aldrich Co., UK 
 
11 0.45µm GDX PVDF filters 
 
Whatman, UK 
 
2.3.2  Method 
2.3.2.1 PAA-Ox5 Synthesis 
PAA was responded in 1:0.05 molar feed with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-
thiol (Oxadiazole, Ox) (monomer: pendant) Figure 2.4.  In short, the PAA dissolution 
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was achieved in 1:1 (v/v) (methanol 25 mL: chloroform25mL) with stirring for 10 min, 
subsequently Trimethylamine (2 mL) was added. The reaction that emanated was 
stirred at room temperature for 0.5 h. The dissolution of 5-(4-chlorophenyl)-1,3,4-
oxadiazole-2-thiol was recorded in 1:1 (v/v) methanol(10mL): chloroform(10mL) and 
an additional drop wise to the polymer solution over 0.5 h. The response was stirred at 
ϯϳ ˚C for ϭϴ h͘ The using a rotary evaporator an evaporation of the solvent was done 
on a reduced pressure, the washing of polymer residue was done three times with 
(10mL) diethyl ether and dried effectively. The dissolution of the residue was done in 
deionised water and thoroughly dialysed utilizing visking membrane 12-14 kDa against 
deionised water for 24 h. 
2.3.2.2  Nuclear magnetic resonance spectroscopy (NMR) 
1H NMR was executed on all modified polymers in deuterated (D2O) (15 mgmL-1) at 25 
0C, utilizing a Bruker 400MHz Ultra shield NMR spectrometer (Bruker BioSpin, 
Germany). Sonication of models utilizing a Soniprep 150 (MSE Ltd, UK) was undertaken 
for 10 mins to ensure that the polymers were completely dissolved in the deuterated 
methanol earlier than the examinations. 
2.3.2.3 Fourier transform infrared spectroscopy (FTIR) 
Fourier Transform Infrared Spectroscopy (FTIR) is a system which has been widely 
used by chemists to identify the presence of certain functional groups in a sample that 
can be in solids, liquids or gaseous state. FTIR spectroscopy offers qualitative and 
quantitative analysis for organic and inorganic compounds, polymers and polymer 
blends (Shaikh and Agrawal, 2014). In this chapter FTIR examinations of all the 
polymers was committed with a Perkin Elmer (Spectrum BX, UK), fitted with a 
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diamond powder tip. The polymers (5 mg) were placed under the diamond tip and 20 
scans were run following a background correction. 
2.3.2.4  Photon correlation spectroscopy and zeta potential measurement 
(PCS,ZS) 
Particle size of the nano aggregates was measured using photon correlation 
spectroscopy and transmission electron spectroscopy. One of the important methods 
used to measure the surface charge of nanoparticles where the stability of these 
particles is determined by measuring the zeta potential. 
Hydrodynamic diameters and zeta potential Density were completed using a photon 
correlation spectrometer (PCS, Zetasizer Nano-ZS, Malvern Instruments, UK). Models 
were Thinned in deionised water to make 1 mgmL-1 of polymer and sonicated for 30 s 
before calculating the size and surface charge of the polymer at 25 °C. 1 mL of sample 
was localized in screw-top glass vials and hydrodynamic radius, PDI and zeta potential 
of models were calculated during the synthesis process (Hoskins et al. 2012b). 
2.3.2.5 Critical aggregation concentration (CAC) as a function of PAA 
molecular weight 
2.3.2.5.1 Critical aggregation concentration using methyl orangehydrophobic probe 
This approach was a reworking of Uchegbu͛s approach (Uchegbu & Schätzlein, 2006). 
A stock solution of methyl orange (25 µM) was arranged with sodium tetraborate 
buffer (0.02 M, pH 9.4) in deionised water. The solution was settled in a sonic bath for 
3h. Twenty two concentrations of altered polymers (0.0195 mgmL-1 - 5 mgmL-1) were 
created using the methyl orange solution as the diluent. Each modal was probe 
sonicated for 10 min and allowed to cool for 5 min to room temperature. The polymer 
46 
 
solutions were examined in a UV-2600 UV-VIS(NIR) spectrometer (Shimadzu, 
Germany) and their maximum absorbance was reported (350 nm - 600 nm). The 
methyl orange stock solution was used as the control. The existence of hypochromic 
shift was resulted by contrasting the polymer solution wavelength maxima with the 
λmax of methyl orange stock solution (465 nm). 
 
2.3.2.5.2 Surface tension 
The measuring of surface tension of the polymer  is  method  used to identify the CAC  
which made up in aqueous solution ( 0.0195 mgmL-1 ʹ 5 mgmL-1) were prepared and 
sonicated for 10 min for the PAA 15kDa , 17.5 kDa, 20 min for 120kDa and 30 min for 
900kDa  before cooling to room temperature. The surface tension of polymer solutions 
was measured at 25 °C using a torsion balance (OS, White Electrical Instrument Co, 
London). The platinum ring was cleaned with ethanol and distilled water prior to 
analysis of each sample. The measurement was recorded in triplicate for each polymer 
solution to get an average value. 
2.3.2.6 Drug loading  
Polymer dissolved in deionised water (1 mgmL-1, 3 mgmL-1 and 6 mgmLо1 ) with  probe 
sonicated for 10 min. Propofol was added at 1:1, 5:1 and 10:1 initial drug: polymer 
weight ratios and the drug-polymer solutions were probe sonicated for a further 10 
min͘ After cooling to room temperature, the solution was filtered using Ϭ͘ϰϱ μm 
syringe filters (with pre-filters) to remove any excess drugs. 
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2.3.2.6.1 Quantification of Propofol 
The drug loading capacity of the self-assemblies was determined using high 
performance liquid chromatography (HPLC) (Shimadzu prominence UFLC, UK), as 
previously reported by Qu and . A RP Zorbax ODS 250 mm x 46 mm x 5 µm HPLC 
column (Hichrom, UK) was used with flow rate of 1 mLmin-1 (80:20 v/v methanol 
:water) in an isocratic mode. The samples were diluted with mobile phase and 20 µL 
was injected onto the column. The amount of propofol present in the samples was 
determined by comparing to a standard calibration carried out previously with 
propofol dissolved in methanol (4 µgmL-1 ʹ 250 µgmL- 1), R2 = 0.9857 Figure 2-4. 
Polymer solutions of 1 mgmL1-, 3 mgmL-1 and 6 mgmL-1 were organized in 4 mL 
aliquots utilizing deionized water as the diluting. Every sample was sonicated for 10 
mins to permit maximum solubilisation and allowing aggregation to happen. 
Subsequently suitable amount of propofol was put together in 1:1, 5:1, and 10:1 drug: 
polymer ratios. The solution of drug-polymer were sonication for 10 min. Next, 
solution were filtered through 0.45 nm to gathered of any excess undissolved drug, all 
analyses was done by using HPLC see Figure 2-4 and Table 2-2.  
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Figure 2-4: Calibration curve of propofol at 229 nm 
 
Table 2-2 Polymer solutions of 1mgmL-1, 3mgmL-1 and 6mgmL-1 were organized in 
deionized water 
Polymer Propofol amount (mg)   
 1:1  5:1 10:1 
1 mgmL-1 1 mg 5 mg 10 mg 
3 mgmL-1 3 mg 15 mg 30 mg 
6 mgmL-1 6 mg  30 mg 60 mg 
 
 
2.3.2.6.2 Quantification of griseofulvin  
This method was an adaptation of Trimaille͛s method (Trimaille & Möller,2006). The 
samples were passed through a RP Phenomenex C18 250 mm x 46 mm x 5 µm HPLC 
column and detected at 293 nm (Shimadzu prominence UFLC, UK). The mobile phase 
y = 656151x - 141410 
R² = 0.9991 
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(45:55 v/v) acetonitrile: 45 mm potassium dihydrogen phosphate made up in water 
and pH adjusted to pH 3 with orthophosphoric acid) ran at a rate of 1 mLmin-1. The 
samples were diluted with mobile phase and 20 µL was injected onto the column, the 
resultant peak at 9.5 min was analysed. The quantification of griseofulvin present in 
the samples was determined from a standard calibration of griseofulvin in mobile 
phase (0.6 µgmL-1 ʹ 10 µgmL-1), R2 = 0.9987 Figure 2-5. 
 
Figure 2-5: Standard curve of griseofulvin 
 
2.3.2.7 In vitro drug release from nano-aggregates 
Dynamic dialysis procedure has been used to determine the rates of drug release from 
polymers formula. Briefly, drug loading was carried out at 1:10 polymer:drug ratio and 
polymer concentration at 6 mgmLо1 polymer concentration 2 mL of each sample was 
transferred into a dialysis tube (MW cut off = 12000-14000 Da). Subsequently, the 
polymer containing dialysis tube was dialyzed against 200 mL deionised water for 24 h 
with stirring at different temperatures. 1 mL of the external deionised water was 
y = 383962x 
R² = 0.9987 
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periodically sucked up and replaced with 1 mL of fresh deionised water. The amount of 
the released drug was determined by using HPLC. Equation 2-1 describes the rate of 
release of the drug from optimum formula. 
Equation 2-1 Rate of release of the drug. 
 
 
2.4 Results 
2.4.1 Synthesis and Characterisation of PAA-Ox5 
PAA-Ox5 polymers were fabricated through an easy substitution reaction onto the 
primary amines in the parent PAA structure and the chloride functionality of the 
oxadiazole compound Figure 2-6. 
 
Figure 2-6: Chemical synthesis of PAA-Ox5 
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The percentages of yield of PAA Table 2-3 was calculated as next :- % Yield = (Product 
weight / Weight of reactants ) X 100 % 
Table 2-3 show the percentages of yield of PAA for different molecular weight. 
Molecular weight of PAA   Weight of product % yield 
a PAA 15 kDa 1.806 g 8Ϭ 
b PAA 17,5 kDa 1.99 g 84 
c PAA 120 kDa 2.083 g 87.82 
d PAA 900 kDa 1.ϳ g ϳϰ.2 
 
The polymer structure was confirmed using NMR. The NMR spectra for the different 
molecular weight amphiphiles compared to the parent PAA are shown in . The spectra 
observed et all molecular weights was comparable after oxadiazole attachment had 
been carried out. Peaks were observed at 0.75 ppm, 2.50 ppm, 3.00 ppm, 1.40 ppm 
and 1.50 ppm which is attributable to the respective CH2 and CH groups in the homo 
polymer backbone.  Also, peaks were observed between at 7.25-7.75 ppm are ascribed 
to the aromatic CH sets located in the oxadiazole pendant collection, see Figure 2-7 
(A1)(PAA 15 kDa) and (A2) PAA-Ox5 15 kDa), Figure 2-8  (B1)(PAA 17.5 kDa)and (B2) 
(PAA-Ox5 17.5 kDa), Figure 2-9 (C1) (PAA 120 kDa) and (C2)( PAA-Ox5 120 kDa), 
Figure 2-10 (D1) (PAA 900 kDa) and (D2)(PAA-Ox5 900 kDa),. An observation of the 
proton on the ʹSH set of the oxadiazole pendant was not made on this field, possibly 
as a result of quick exchange involving the thiol and D2O solvent. 
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Figure 2-7: The spectra of 1H NMR spectroscopy of (A1) PAA 15kDa , (A2) PAA-Ox5 15 
kDa carried out on 400MHz NMR at 25 °C 
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Figure 2-8: The spectra of 1H NMR spectroscopy of (B1) PAA 17.5 kDa, (B2)PAA-Ox5  
17.5 kDa carried out on 400MHz NMR at 25 °C 
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Figure 2-9: The spectra of 1H NMR spectroscopy of (C1) PAA 120 kDa, (C2)PAA-Ox5 
120 kDa carried out on 400MHz NMR at 25 °C 
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Figure 2-10: The spectra of 1H NMR spectroscopy of (D1) PAA 900 kDa, (D2)PAA-Ox5 
900 kDa carried out on 400MHz NMR at 25 °C 
 
In order to identify the functional groups present within the polymer structure, FTIR 
analysis was carried out between 4000 cm-1 ʹ 650 cm-1 to detect the specific functional 
groups existing. See  Figure 2-12, Figure 2-13 ,2-13 and Figure 2-14. 
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Figure 2-11: The spectra of (A1) PAA 15kDa and (A2) PAA-Ox5 15kDa polymer structure 
using diamond tripped ATR-FTIR (64scan) 
A1 
A2 
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Figure 2-12: The spectra of (B1) PAA 17.5 kDa and (B2) PAA-Ox5 17.5 kDa polymer 
structure using diamond tripped ATR-FTIR (64scan) 
 
B1 
B2 
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Figure 2-13: The spectra of(C1) PAA 120 kDa and (C2)PAA-Ox5 120 kDa polymer 
structure using diamond tripped ATR-FTIR (64scan) 
 
 
 
C1 
C2 
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Figure 2-14: The spectra of (D1) PAA 900 kDa and (D2) PAA-Ox5 900 kDa polymer 
structure  using diamond tripped ATR-FTIR (64scan) 
 
Here, characterisation distinguishing feature peaks were observed at ϯϮϳϵ cm-1 and 
Ϯϴϰϵ cm-1 arising from the respective N-H stretching and C-H stretching in the PAA 
backbone. Also, peaks determined at 1ϱϴ0 cm-1 and showed that hydrophobic 
pendant collection involvement had been attained as a result these peaks being 
D1 
D2 
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associated to the bending and stretching vibrations of the aromatic ring C=C located 
in the oxadiazole structure. 
2.4.2 Critical aggregation concentration (CAC) 
Critical aggregation concentration (CAC) has the equivalent value of amphiphilic 
polymers. Hydrophobic-hydrophobic interactions and nonʹpolar between the 
aqueous media and amphiphilic polymer are the force behind the aggregate 
forming. Investigation of the capability of the nano-aggregates to encapsulate of 
hydrophobic drug molecules has been done by using many types of technical 
(Gaucher et al. 2005). 
2.4.2.1 Methyl orange 
The ability of the polymeric amphiphiles to form aggregates in aqueous solutions 
was investigated using a hydrophobic methyl orange probe. Literature has shown 
that incorporation of methyl orange into polymeric aggregates results in a 
hypochromic shift which can be observed on the UV spectra and is indicative of the 
critical aggregation concentration. 
The lambda max wavelength for methyl orange mixed with PAA 15 kDa, PAA 17,5 
kDa, 120 kDa and 900 kDa  are shown in Figure 2-15. As observed this particular 
method did not result in a shift ʹ the increase in wavelength at high polymer 
concentration is merely due to the turbidity of the solutions. Hence, it was decided 
to use a different method for CAC measurement ʹ surface tension. 
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Figure 2-15: Effect of PAA-Ox5 (15 kDa, 17.5 kDa ,120 kDa and 900 kDa  on the peak 
absorbance of methyl orange at 465 nm (n=3, ave ± SD) 
 
2.4.2.2 Surface tension 
Surface tension is the attraction between particles that make the surface layer of 
any liquid, resulting in a minimal surface area. Other molecules in the medium 
move in all directions. However, this does not apply at the liquid air interface. Liquid 
surface molecules are less surrounded with molecules and so, cohesive forces can 
only be established with those molecules while they are adjacent or below. Surface 
tension occurs at the interface while inward force is experienced by the molecules 
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resulting in a free energy state. Increasing temperature and pressure lead to 
decreases in surface tension, and at higher pressure the temperature dependence 
of surface tension is less evident (Park et al. 2007). 
In order to increase the surface tension, there is need for an increase in free energy. 
Surface tension change in the aqueous environment, with increased in polymers 
concentration were observed (Churchill 1998).  
The hydrophobic chains form the core of the micelle and are shielded from the 
aqueous environment by the surrounding shell composed of the hydrophilic groups 
that serve to maintain solubility in water. 
For a micellar system at normal temperatures the entropy term is by far the most 
important in determining the free energy changes. The explanation most generally 
accepted for the entropy change is concerned with the structure of water. Water 
possesses a relatively high degree of structure owing to hydrogen bonding between 
adjacent molecules. If an ionic or strongly polar solute is added to water it will 
disrupt this structure, but the solute molecules can form hydrogen bonds with the 
water molecules that more than compensate for the disruption or distortion of the 
bonds existing in pure water. Ionic and polar materials thus tend to be easily soluble 
in water. No such compensation occurs with non-polar groups and their solution in 
water is accordingly resisted, the water molecules forming extra structured clusters 
around the non-polar region. This increase in structure of the water molecules 
around the hydrophobic groups leads to a large negative entropy change. To 
counteract this and achieve a state of minimum free energy, the hydrophobic 
groups tend to withdraw from the aqueous phase either by orientating themselves 
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at the interface with the hydrocarbon chain away from the aqueous phase or by 
self-association into micelles (Aulton,2002). 
 This tendency for hydrophobic materials to be removed from water as a result of 
the strong attraction of water molecules for each other and not for the hydrophobic 
solute, has been termed hydrophobic bonding. However, because there is, in fact, 
no actual bonding between the hydrophobic groups the phenomenon is best 
described as the hydrophobic effect. When the non-polar groups approach each 
other until they are in contact, there will be a decrease in the total number of water 
molecules in contact with the non-polar groups. The formation of the hydrophobic 
bond in this way is thus equivalent to the partial removal of hydrocarbon from an 
aqueous environment and a consequent loss of the ice-like structuring that always 
surrounds the hydrophobic molecules. The increase in entropy and decrease in free 
energy that accompany the loss of structuring make the formation of the 
hydrophobic bond an energetically favourable process (Aulton,2002).  
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Figure 2-16: Surface Tension results for  ♦ PAA 15 kDa , ■ PAA 17.5 kDa, ▲PAA 120 
kDa and X 900 kDa  at Ϯϱ ϶C, ;nсϯ, ave ц SDͿ 
The surface tension of water is 0.072 N/m. The critical aggregation concentration is 
measured as the point of inflexion in the surface tension as in Table 2-4. Here it is 
observed that increasing molecular weight of the polymer (at fixed molar ratio 
modification with oxadiazole) resulted in a decrease in CAC value. This is probably 
because there is a shift in the hydrophilic-lipophilic balance and thus there is less 
tendency to spontaneously aggregate at the higher molecular weight. This data 
indicates that the most stable aggregates are formed at the lower molecular weight.  
The surface tension of a surfactant solution decreases progressively with the 
increase of concentration as more surfactant molecules enter the surface or 
interfacial layer. However, at a certain concentration, this layer becomes saturated 
and an alternative means of shielding the hydrophobic group of the surfactant from 
the aqueous environment occurs through the formation of aggregates of colloidal 
dimensions, called micelles. Figure 2-16 shows the surface tension varied the 
molecular weight of PAA-Ox5. Many properties of polymers are known to be 
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molecular weight dependent. The increases in molecular weight led to a decrease in 
surface tension due to an increase in entropy (Moreira & Demarquette,2001).            
Table 2-4 Show the PAA surface tension with water at 21 0 C (n=3). 
 Molecular weight of PAA 
Ox5 mgmL-1 
Value of surface tension 
N/m 
Appearance in solution 
above CAC 
a 15 kDa   0.625 mgmL-1, (0.067) Colourless clear solution 
b 17.5 kDa   0.3125 mgmL-1, (0.0651) Colourless clear solution 
c 120 kDa   0.0390 mgmL-1, (0.0611) Yellow clear solution 
d 900 kDa 0.0195mgmL-1, (0.055) Colourless clear solution 
 
2.4.3  Drug loading 
2.4.3.1  Propofol 
After the nano-aggregates were loaded with Propofol, the resultant peak at 5 min 
Figure 2-17 was observed at 229 nm (Shimadzu prominence UFLC, UK). 
 
Figure 2-17: Drug loading of propofol representative spectra using HPLC 
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The polymer concentration has effect on drug loading, in Figure 2-18 the highest 
percentage of drug loading was 12,169 mgmL-1 at (6 mgmL-1 polymer : 60 mg/ml 
initial drug feed) for the PAAOx5 15 kDa / polymer and propofol respectively. While, 
the lower loading (0.592 mgmL-1) was recorded at 1 mgmL-1:1 mgmL-1 
polymer,propofol respectively, Table 2-5.  
 
Figure 2-18: Drug loading of propofol in 0.25 % with Poly (allylamine) PAA (15 kDa) 
at RT (n=3)  
 
 
Table 2-5 Drug loading of propofol in 0.25 % with Poly (allylamine) PAA (15 kDa) at 
RT. 
Drug:polymer ratio 1 mgmL-1 3 mgmL-1 6 mgmL-1 
1:1 0.592 1.62 2.545 
1:5 1.526 3.13 3.269 
1:10 3.155 8.953 12.169 
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Figure 2-19 shows the percentages of drug loading of PAA-OX5-17.5 kDa to prpopfol 
was (18.7 mgmL-1) at 6 mgmL-1 polymer: 60 mgmL-1 initial drug feed), while only 1.7 
mgmL-1 was solubilised at lower polymer concentrations.  This result indicated the 
drug loading is depending on molculare wight of polymer. This result is due to the 
increase in lenght chain of hydrophilic of polymer Table 2-6. 
 
Figure 2-19: Drug loading of propofol in 0.25 % with Poly (allylamine) PAA (17.5 kDa) 
at RT (n=3)  
Table 2-6 drug loading of propofol in 0.25 % with Poly(allylamine) PAA (17.5 kDa)at 
RT 
Drug:polymer ratio 1 mgmL-1 3 mgmL-1 6 mgmL-1 
1:1 1.7 3.72 4.848 
1:5 2.2 4.04 13.758 
1:10 3.1 5.52 18.7 
 
Figure 2-20 shows the maximum concentration of propofol drug loading in polymer 
concentration of PAA-OX5- 120 kDa. Comparing the drug loading values is observed 
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the loading of propofol in 6 mgmL-1 and feed ratio 10:1 was 25.74 mgmL-1 ,while, at 
lower concentration 1 mgmL-1 and feed ratio 1:1 was 2.3 mgmL-1, due to the 
increase in chain length see Table 2-7. 
 
Figure 2-20: Drug loading of propofol in 0.25 % with Poly (allylamine) PAA (120kDa) 
at RT (n=3 ) 
 
Table 2-7 Drug loading of propofol in 0.25 % with Poly (allylamine) PAA (120 kDa) at 
RT. 
Drug: polymer ratio 1 mgmL-1 3 mgmL-1 6 mgmL-1 
1:1 2.3 5.06 7.66 
1:5 3.1 8.02 11.31 
1:10 4.43 18.02 25.74 
 
The results revealed that THE increase in the molecular weight led to increase in 
drug loading, this was due to an increase in chain length of polymers (Wong et al. 
2017). 
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Characterisation of drug loaded aggregates of propofol with PAA-OX5 was indicated 
by using size and zeta potential Figure 2-21. 
Size of PAA-OX5 alone and PAA-OX5 loaded with propofol is shown in Table 2-8. The 
data show that size of PAA-OX5 alone was smaller than PAA-OX5 loaded with 
propofol. The effect of drug loading on the resulting PAA-OX5 size was clear with 
propofol formulations. Increasing the drug loading caused an increase in the mean 
diameter of the copolymer self- assemblies.  
 
 Figure 2-21: Zeta potential and size of PAA 17.5 kDa (n=3) 
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Table 2-8 Zeta potential and size of Polymer (15 kDa with propofol) at R .T (n=3, 
±SD) 
Concentration 
of polymer 
Drug: 
polymer 
ratio 
Size  
PAA-OX5 
(±SD) 
                PAA-OX5 with propofol 
Size S.D pdI S.D Zeta;ζͿ 
Mv(±SD) 
1 mgmL-1 (1:1) 40.04 60.15 0.6718 0.202 0.0.006 28.26 
1 mgmL-1 (1:5) 51.55 95.434 0.5196 0.178 0.009 28.07 
1 mgmL-1 (1:10) 70.76 117.5 0.6471 0.192 0.009 24.06 
3 mgmL-1 (1:1) 44.6 87.72 0.7654 0.186 0.012 20.3 
3 mgmL-1 (1:5) 86.04 101.4 1.323 0.145 0.002 17.86 
3 mgmL-1 (1:10) 128.60 170.3 4.541 0.448 0.053 15.44 
6 mgmL-1 (1:1) 74.18 131.8 1.709 0.412 0.052 17.66 
6 mgmL-1 (1:5) 83.65 111.7 4.900 0.6512 0.053 16.71 
6 mgmL-1 (1:10) 139.61 172.6 5.505 0.1281 0.083 16.1 
 
Table 2-9 shows the size values of the PAA-OX5 17.5 kDa with propofol , which had 
the highest value (172.6 nm) for the concentration (6 mgmL-1) and feed ratio 1:10  
and the lowest value was (60.15 nm) for the concentration of 1 mgmL -1 and feed 
ratio 1:1. 
The size of PAA-OX5 (without propofol was smaller than the size  with propofol as 
explain in Table 2-8. The zeta potential values were record the highest value (28.26 
mV) at low concentration while the lowest values (16.1 mV) were recorded for 6 
mgmL-1 concentration and feed ratio of 1:10.  
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Table 2-9 Zeta potential and size  of polymer (17.5 kDa with propofol) at RT(n=3, 
±SD) 
Concentration 
of polymer 
Drug: 
polymer 
ratio 
Size  
PAA-OX5 
(±SD) 
                      PAA-OX5-with propofol 
Size nm S.D pdl S.D Zeta;ζͿ 
Mv(±SD) 
1 mgmL-1 1:1 59.38 68.35 1.146 0.167 0.018 26.0 
1 mgmL-1 1:5 90.06 101.9 1.345 0.132 0.029 24.4 
1 mgmL-1 1:10 101.00 121.2 29.06 0.424 0.026 28.76 
3 mgmL-1 1:1 56.04 87.72 0.222 0.212 0.006 17.96 
3 mgmL-1 1:5 83.61 101.4 1.970 0.291 0.007 17.06 
3 mgmL-1 1:10 100.60 144.7 1.332 0.422 0.058 17.4 
6 mgmL-1 1:1 88.07 117.01 4.799 0.340 0.069 19.56 
6 mgmL-1 1:5 90.55 111.7 9.928 0.452 0.093 19.5 
6 mgmL-1 1:10 116.76 172.6 57.71 0.052 0.087 20.6 
 
Table 2-10 shows the change in the size values of the PAA 120 kDa with the 
concentration change. The highest values were (186.7 nm) at 6 mgmL-1 and feed 
ratio 1:10, whereas the lowest values (35.22 nm) were at 1 mgmL-1 and feed ratio 
(1: 1) for the drug. 
The highest value of zeta potential was 28.6 mV for the 1 mgmL-1 concentration and 
feed ratio 1: 10 for the drug, while the lowest values 14.3 nm were at 6 mgmL-1 and 
feed ratio 1: 5 for the drug. 
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Table 2-10 Zeta potential and size  of Polymer (120,000)+ propofol at R .T (n=3, 
±SD). 
Concentration 
of polymer 
Drug: 
polymer 
ratio 
Size PAA-
OX5 
(±SD) 
                         PAA-OX5-with propofol 
Size nm S.D pdl S.D Zeta;ζͿ 
Mv(±SD) 
1 mgmL-1 1:1 27.33 35.22 0.5597 0.366 0.0.005 28.6 
1 mgmL-1 1:5 48.09 54.13 0.5004 0.27 0.0005 25.0 
1 mgmL-1 1:10 55.7 57.55 0.5551 0.790 0.044 23.8 
3 mgmL-1 1:1 112.00 144.4 22.44 0.72 0.166 26.1 
3 mgmL-1 1:5 150.04 164.8 10.76 0.177 0.151 25.2 
3 mgmL-1 1:10 167.21 175.7 6.09 0.581 0.028 22.3 
6 mgmL-1 1:1 117.63 132.6 61.773 0.662 0.022 25.0 
6 mgmL-1 1:5 130.05 151.66 97.2 0.803 0.101 21.1 
6 mgmL-1 1:10 160.11 186.7 5.003 0.700 0.036 20.9 
 
The poly disparity index of the PAA-Ox5 demonstrates the mono disparity of the 
nano-aggregation is not prevailing for long time. PAA-Ox5 zeta potential quoted and 
displayed (+26 mV), this elevated value is related to the existence of active amine 
accumulated in PAA backbone. 
Table 2-11 showed the size values of the PAA-OX5 120 kDa with propofol , which 
had the highest value (186.11 nm) for the concentration (6 mgmL-1) and feed ratio 
of 1:5  and the lowest value was (27.33 nm) for the concentration of 1 mgmL-1and 
feed ratio of 1:1.  
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The zeta potential values were record the highest value (28.6 mV), while the lowest 
values (20.9 mV) were recorded for 6 mgmL-1 concentration and feed ratio (1:1). 
The next table show the values of size and zeta potential of PAA-OX5 which has high 
molecular weight 900 kDa, the size was recorded the same values as the low 
molecular weight this due to  the aggregates formed were too large to filter and 
hence this molecular weight was disregarded. 
Table 2-11 Zeta potential and size of Polymer (900.000)+ propofol at R .T (n=3, ±SD) 
Concentration 
of  Polymer 
Drug: 
polymer 
ratio 
Size  
PAA-OX5 
(±SD) 
                       PAA-OX5-with propofol 
Size nm S.D pdl S.D Zeta  
mV;ζͿ (±SD) 
1 mgmL-1 1:1 44.91 69.94 0.4620 0.231 0.0.005     27.8 
1 mgmL-1 1:5 46.73 62.01 0.6700 0.250 0.0005     27.4 
1 mgmL-1 1:10 55.03 55.16 0.833 0.307 0.044     20.8 
3 mgmL-1 1:1 141.4 162.9 40.67 0.479 0.166     25.1 
3 mgmL-1 1:5 98.6 115.3 19.88 0.360 0.151     22.2 
3 mgmL-1 1:10 90.0 108.8 5.910 0.318 0.028     23.1 
6 mgmL-1 1:1 88.2 131.6 1.518 0.175 0.022     17.0 
6 mgmL-1 1:5 95.6 117.85 197.2 0.215 0.101     19.1 
6 mgmL-1 1:10 157.8 194.9 4.583 0.395 0.036    21.2 
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2.4.3.2 Griseofulvin 
Drug loading for griseofulvin was achieved at the 1 mgmL-1 ,  3 mgmL-1 and  6 mg 
mL-1  polymer concentration and 1:1, 5:1 and 10:1 initial drug: polymer feed ratio. 
 
Figure 2-22: Drug loading of Griseofulvin in 0.25 % with Poly(allylamine) PAA 
(15kDa) at room temperature, (n=3) 
 
 
Table 2-12 shows the concentration of griseofulvin in 0.25 % drug loading in 
polymer PAA 15kDa concentration of PAA-OX5- griseofulvin, Figure 2-22. Comparing 
the drug loading values is observed the loading of griseofulvin in 6 mgmL-1 and feed 
ratio 10:1 was 5.1 mgmL-1, while, at lower concentration 1 mgmL-1 and feed ratio 
1:1 was 0.22 mgmL-1.   
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Table 2-12 Drug loading of griseofulvin in 0.25 % with Poly (allylamine) PAA (15 kDa) 
at RT. 
Drug:polymer ratio 1  mgmL-
1 
3 mgmL-1 6 mgmL-1 
1:1 0.11 0.14 0.16 
1:5 0.16 0.15 0.20 
1:10 0.14 0.27 0.32 
 
The concentration of drug loading of polymer 17.5 kDa at 1, 3 and 6 mgmL-1 ,its 
describe in Figure (2-17) and  Table 2-13. 
 
Figure 2-23: Drug loading of griseofulvin in 0.25 % with Poly (allylamine) PAA (17.5 
kDa) at R. T, (n=3) 
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Table 2-13 Drug loading of griseofulvin in 0.25 % with Poly (allylamine) PAA (17.5 
kDa) at RT. 
Drug:polymer ratio 1 mgmL-1 3 mgmL-1 6 mgmL-1 
1:1 0.19 0.25 0.34 
1:5 0.28 0.96 1.28 
1:10 0.39 1.11 1.51 
 
 
Figure 2-24: Drug loading of Griseofulvin in 0.25 % with Poly(allylamine) PAA 
(120kDa)  at  R . T, (n=3, ±SD) 
Table 2-14 Drug loading of griseofulvin in 0.25 % with Poly (allylamine) PAA (120 
kDa) at RT.  
Drug:polymer ratio 1  mgmL-1 3 mgmL-1 6 mgmL-1 
1:1 0.22 0.35 0.84 
1:5 0.35 1.70 3.06 
1:10 0.84 3.50 5.10 
 
 
0
1
2
3
4
5
6
1 2 3
G
rie
so
fo
ul
ve
n 
co
nc
en
tr
at
io
n 
m
g/
m
L 
Drug : Polymer ratio 
Drug loading of PAA 120 kDa 
1mg/mL
3mg/mL
6mg/mL
77 
 
Table 2-14 shows the concentration of  griseofulvin in 0.25 % drug loading in each 
polymer concentration of PAA-OX5- 120 kDa loading to  griseofulvin. Comparing the 
drug loading values is observed the loading of griseofulvin in 6 mgmL-1 and feed 
ratio 10:1 was 5.1 mgmL-1, while, at lower concentration 1 mgmL-1 and feed ratio 
1:1 was 0.22mgmL-1.   
Size and zeta potential drug loaded aggregates was shown in Table 2-15. The 
change in the size values of the PAA 15kDa polymer with the concentration change 
appeared the highest values were (112.65 mV),(121.33 mV± 2.819) at 6 mgmL-1 for 
PAA-OX5 and PAA-Ox-propofol, respectively and feed ratio 1:10, while  the lowest 
values was (44.72 mV) and feed ratio 1:5 for the PAA-OX5 and (49.16 mV±0.501) for 
the PAA-Ox-propofol   was at 1 mgmL-1 and feed ratio (1: 1) for the drug. 
The highest values of zeta potential were 29.7 mV for the 1 mgmL-1 concentration 
and feed ratio 1:10 for the drug, while the lowest values of zeta potential was 15.8 
mV were at 6 mgmL-1 and feed ratio 1: 10 for the drug. 
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Table 2-15 Zeta potential and size  of Polymer (15000)+ griseofulvin at R .T, (n=3, 
±SD) 
Concentration 
of polymer 
 
Drug: 
polymer 
ratio 
Size 
potential 
PAA-OX5 
Size potential 
PAA-OX5 
propofol 
         PAA-OX5-with propofol 
S.D pdl S.D Zeta;ζͿ  
mV (±SD) 
1 mgmL-1 1:1 47.66 49.16 0.501 0.25 0.01 28.0 
1 mgmL-1 1:5 44.72 52.18 1.009 0.23 0.01 21.3 
1 mgmL-1 1:10 65.88 73.09 0.598 0.49 0.01 29.7 
3 mgmL-1 1:1 61.19 79.99 0.989 0.31 0.02 22.9 
3 mgmL-1 1:5 80.01 104.11 0.862 0.27 0.01 26.0 
3 mgmL-1 1:10 93.67 105.6 0.655 0.20 0.01 27.6 
6 mgmL-1 1:1 86.08 111.11 0.702 0.21 0.01 17.9 
6 mgmL-1 1:5 97.22 117.44 1.11 0.34 0.05 19.7 
6 mgmL-1 1:10 112.65 121.33 2.819 0.281 0.014 15.8 
 
Table 2-16 showed the size values of the PAA-OX5 17.5kDa with propofol, which 
had the highest value (130.3 nm) for the concentration (6 mgmL-1) and feed ratio 
(1:5) and the lowest value was (52.47 nm) for the concentration of 1 mgmL-1 and 
feed ratio(1:1). The zeta potential values were record the highest value (33.1 mV), 
while the lowest values (16.5 mV) were recorded for 6 mgmL-1concentration and 
feed ratio (1:1). 
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Table 2-16 Zeta and size  potential of Polymer (17.500)+ griseofulvin at R .T. (n=3, 
±SD).  
Concentration 
of polymer 
Drug: 
polymer 
ratio 
Size  
PAA-OX5 
Size potential 
PAA-OX5 
propofol 
          PAA-OX5-with propofol 
S.D pdl S.D Zeta;ζͿ  
mV (±SD) 
1 mgmL-1 1:1 48.15 52.47 0.32 0.26 0.01 31.4 
1 mgmL-1 1:5 48.77 54.53 1.02 0.28 0.01 29.3 
1 mgmL-1 1:10 67.17 71.80 0.77 0.16 0.02 33.1 
3 mgmL-1 1:1 64.03 91.90 1.60 0.41 0.01 20.9 
3 mgmL-1 1:5 88.83 109.7 1.25 0.32 0.01 23.2 
3 mgmL-1 1:10 95.19 91.63 0.83 0.21 0.01 28.4 
6 mgmL-1 1:1 89.11 103.2 0.93 0.45 0.02 16.5 
6 mgmL-1 1:5 121.12 130.3 1.07 0.31 0.04 18.5 
6 mgmL-1 1:10 117.16 123.1 4.96 0.24 0.02 20.8 
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Table 2-17 illustrates the change in the size values of the PAA 120kDa with propofol   
with the concentration change. 
Table 2-17 Zeta and size  potential of Polymer (120,000)+ griseofulvin at  R .T (n=3, 
±SD).   
Concentration 
of polymer 
 
Drug: 
polymer 
ratio 
Size  
PAA-OX5 
Size  
PAA-OX5 
propofol 
         PAA-OX5-with propofol 
S.D pdl S.D Zeta;ζͿ  
mV (±SD) 
1 mgmL-1 1:1 51.03 59.37 0.55 0.38 0.01 28.8 
1 mgmL-1 1:5 53.66 60.25 0.24 0.80 0.14 29.7 
1 mgmL-1 1:10 63.17 79.97 2.49 0.32 0.04 29.9 
3 mgmL-1 1:1 75.91 80.43 1.43 0.34 0.04 29.0 
3 mgmL-1 1:5 83.07 97.41 0.99 0.22 0.01 24.0 
3 mgmL-1 1:10 89.55 92.54 1.53 0.20 0.01 23.1 
6 mgmL-1 1:1 86.52 91.46 0.70 0.20 0.01 23.4 
6 mgmL-1 1:5 92.05 107.6 1.42 0.53 0.04 14.3 
6 mgmL-1 1:10 123.31 196.6 3.790 0.44 0.035 17.7 
The highest values were (196.6 nm) at 6 mgmL-1 and feed ratio 1:10, whereas the 
lowest values (59. 37 nm) were at 1 mgmL-1 and feed ratio (1: 1).  
The highest values of zeta potential were 29.7 nm for the 1 mgmL-1 concentration 
and 1: 10 for the drug, this high value is related to the presence of active amine 
accumulated in PAA backbone, while the lowest values 14.3 nm were at 6 mgmL-1 
and feed ratio 1: 5 for the drug.  
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The conclusion from these obtained values can be that the size fits proportionately 
with the concentration while zeta values varied. Further conclusion of these values 
could be that Zeta potential was increased with increasing molecular weight of the 
same concentration at 1 mgmL-1 concentration and load ratio of 1:10. 
2.4.4 Drug release  
2.4.4.1 Drug release of Propofol and Griseofulvin 
In vitro, drug release analyses were completed under ͚sink conditions͛ for all of the 
exquisite formulations. Figure 2-25.  
 
Figure 2-25: The percentages of  drug release of PAA 15 kDa ,PAA 17.5 kDa and 120 
kDa  with propofol at R .T , (n=3, ±SD)   
 
The analyses were completed in different duration and drug release at 48 h was 
(74.3%), 4 h was (53.54%) and 72 h was (35.84%) for PAA 15kDa, 17.5 kDa and 120 
kDa respectively. 
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Figure 2-26: The percentages of drug release of PAA 17.5 kDa at deferent 
temperature with propofol, (n=3, ±SD)  
 
Griseofulvin release was indicated by using HPLC,  release study was conducted in 
aqueous solution  by placing PAA-OX5-griseofulvin  formulation into a visking tubing 
(2 mL, 12-14 KDa) and dialysed against 200 mL of deionised water at (20 oC,37 oC,44 
oC). The PAA-OX5 17.5 kDa was  investigated as in Figure 2-27 and in Figure 2-28. 
The hydrophobic drug formulations showed an initial ͚burst͛ release over the first 4 
h period. Griseofulvin was released consistently throughout the study period until 
0.3314 %. 
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Figure 2-27:  The percentages of drug release of PAA 15000 with griseofulvin at 
room temperature, (n=3) 
 Figure 2-28 shows the percentages of drug release of griseofulvin with   PAA-OX5-
17.5 kDa from formulation at different temperatures. The drug release was 
recorded 5.51 % at 37oC after 5 h, while at 44 oC the percentages was recorded 6.8 
% after 5h.  This results show the  increasing in temperature led to increasing in 
drug release.  
 
Figure 2-28:  The percentages of drug release of griseofulvin with PAA-OX5-17.5 kDa 
from  formulation at different temperatures(n=3) 
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2.5 Discussion  
This study investigated the use of poly(allylamine) amphiphiles at varied molecular 
weight in the development of macromolecules. Four molecular weights were used: 
15,000 Da, 17,500 Da, 120,000 Da and 900,000 Da. Poly(allylamine) (PAA) was 
grafted with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol to act as universal 
hydrophobic drug solubilizers. In this project model drugs included propofol and 
griseofulvin.  Figure 2-23 
 In this study successful synthesis of both PAA-OX5 amphiphile was achieved figure 
2.19, confirmed by NMR and FTIR characterisation.  
 
 
 
 
Figure 2-29: Mechanism of hydrophobic drug molecule encapsulation A) propofol 
and B) griseofulvin 
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It is of signiﬁcant interest to design polymeric micelles that are capable of acting as 
universal delivery vehicles for various potent drugs, which are not in therapeutic 
formulations due to their water-insoluble, hydrophobic natures.  
The consolidation at which micelles first form in solution is termed the critical 
micelle consolidation or CMC. This commencement of micelle formation can be 
noticed by a multitude of tested techniques. The CMC diminishes with a growth in 
the length of the hydrophobic chain. 
The data clearly displays that size of polymers charged with multitude drugs model 
can be varied, changing in particle size allocation was reliant on the drug loading.  
The effect of drug loading on the outcome polymer charge distribution was quite 
understandable with propofol and griseofulvin formulations. Elevating the drug 
loading caused increasing the main charge of the polymer. 
The essential reason for micelle formation is the achievement of a condition of 
minimum free energy. The free energy change, ѐG, of a system is reliant on changes 
in both entropy, S, and enthalpy, H, which are associated with the expression (ѐG = 
ѐH - TѐS). For a micellar system at normal temperatures the entropy term is by far 
the most crucial in deciding the free energy changes (TѐS comprises roughly 90-95% 
of the ѐG value) (Gaucher et al. 2005). 
The clarification most generally accepted for the entropy change is uptight 
alongside the form of water. Water obtains a comparably high degree of structure 
due to hydrogen connecting between abutting molecules. If an ionic or strongly 
polar solute is added to water it will rattle this structure, but the solute molecules 
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can form hydrogen connections alongside the water molecules that more than 
restitution for the disruption or deformity of the existing connections in pure water. 
The propofol and griseofulvin loading drugs into PAA-Ox5 and carried out by 
exploiting hydrophobic drug encapsulated into hydrophobic core of amphiphilic 
polymer by preparing drug: polymer feed ratio 1:1,1:5 and 1:10 and quantified by 
high performance liquid chromatography. In general, all polymers encapsulated 
highest drug levels at higher polymer concentrations and at 10:1 initial drug feed: 
polymer concentration. Figure 2-30 shows the optimal loading concentrations of 
both Propofol and griseofulvin across the polymer molecular weights. Unfortunately 
at (900 kDa) the aggregates formed were too large to filter and hence this 
molecular weight was disregarded. The data showed that at increased molecular 
weight, increased drug loading was possible.  
 
Figure 2-30: Drug loading of propofol and griseofulvin in 0.25 % with Poly 
(allylamine) PAA at R .T, (n=3, ±SD) 
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Griseofulvin solubilisation results are lower than the propofol solubilisation. The 
reason for this is not clear, despite the fact it could be resulting in  the height core 
enlargement upon drug loading due to in bigger accumulation which was then 
taken off during the filtering process (Barnett et al. 2013). 
The drug release from nanoparticles depends on many factors such as diffusion 
from the polymer nanoparticles, desorption of the surface drug polymer 
nanoparticle and a combined degradation/diffusion process. Drug release and 
biodegradation are important in the development of drug delivery systems. A study 
by Barnett shows that drug release is a significant characteristic of a therapeutic 
system. Where scientists found a linear linker between the drug release and the 
absorption of the body. (Lu et al. 2011). In this work, the drug release was 
influenced by polymer molecular weight and drug loading. Polymers with higher 
molecular weight tend to possess slower drug release compared to lower molecular 
weight.  
The molecular weight of the polymer can significantly affects the degree of 
aggregation, the solubility of higher molecular weight polymer in solvent was less 
than that of lower molecular weight polymer. Therefore, the heavier polymer would 
precipitate out faster and the molecular chain would be hardened by not allowing 
the intermolecular interaction of the drug layers around the particles which would 
cause aggregation (Kung ,1997).  
Taking our findings into account, looking at the surface tension data, the aggregates 
formed at high molecular weight are likely to be more unstable upon dilution. 
Hence, it was decided to continue our studies throughout this thesis on PAA-Ox5 
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with molecular weight of PAA as 17,500 Da. This result may be due to the molecular 
weight of the drug propofol (Mw=178 gmoLо1) and griseofulvin (Mw= 353 gmoLо1) 
(Barnett et al. 2012). 
In an identical experiment, Barnett and colleagues constructed PAA amphiphiles 
combined alongside oxadiazole in 5% mole grafting ratios.  They proclaimed CAC 
values between 0.02 mgmL-1- 0.18 mgmL-1 which were dependant on the polymer 
architecture. The factors influencing the value of CAC in a particular medium 
depend largely on the temperature and concentration of the material where 
Micelles is formed at a critical temperature. 
The polydispersity indicator of the PAA-Ox5 demonstrates the monodispersity of 
the nano-aggregation is not dominating for a long time. PAA-Ox5 zeta potential 
calculated and displayed ranging between several values depending on the 
molecular weight of the PAA ʹOX5 and feed ratio of the hydrophobic drug. 
In vitro, drug release analyses of propofol were completed under ͚sink conditions͛ 
for all of the exquisite formulations Figure 2-30. The analyses were completed in a 
duration of 48 h (74.3%)for PAA-OX5 15 kDa, 4 h (53.54%) for PAA-OX5 17.5 kDa 
and 72 h (35.84%) for PAA-OX5 120 kDa. 
Griseofulvin release pursued a very slow. The percentage released of (PAA-Ox5, 15 
kDa) was 0.3314 % after 72 h. Unfortunately at (17.5 kDa) and (900 kDa) there was 
no records any result this due to the aggregates formed were too large to filter and 
hence this molecular weight was disregarded. 
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2.6  Conclusion  
For use as a universal drug solubilising agent PAA 17,500 Da was the optimal chain 
length to use as a PAA-Ox5 construct to give the most stable drug delivery system. 
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CHAPTER THREE 
3 MAGNETIC IRON OXIDE GOLD HYBRID NANOPARTICLE FABRICATION AND MAGNETOMICELLE FORMATION 
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3.1 Introduction 
Magnetic iron oxide nanoparticles (MNPs) have been used as contrast agents for MRI 
due to their ability to improve the visualisation of various conditions particularly 
cancer. Scientific investigation is on-going to find an appropriate means to utilise MNPs 
in magnetic resonance imaging (MRI) motivated cellular hyperthermia. MNPs are the 
emphasis of interest in recent studies as a result of enormous biomedical applications 
(Acar et al. 2005). Among these are drug delivery, biological detection, magnetic bio-
separation, imaging and targeted delivery. MNPs have larger surface range as 
compared to the ratios of volume as a result of their nano-size and the lower surface 
charger at physiological pH but they can quickly aggregate in solution because of their 
magnetic nature. Experiments have exploited the use of MNPs using both EPR effect 
(with passive targeting) as well as surface functionalization to confer site specific 
action to the tumour (active targeting) (Arruebo et al. 2007). 
To reduce the inherent cytotoxicity of MNPs, they are commonly coated with materials 
such as poly(acrylic acid) PAA (Mak and Chen, 2005), dextran (Ciobanu et al. 2012), 
poly(ethylenimine) (PEI) (Wang et al. 2009), silica (Santra et al. 2001), carbon (Mendes 
et al. 2014) or precious metals (e.g. gold or silver) Figure 3-1 (Mandal et al. 2005). 
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Figure 3-1: Schematic representation of gold Iron oxide hybrid nanoparticles 
 
Gold coated hybrid nanoparticles (HNPs) have been shown as promising delivery 
vehicles for chemotherapeutics (Oluwasamni et al. 2017) including gemcitabine which 
is commonly used in pancreatic cancer therapy. The main downfall of HNPs is their 
reduced ability to carry drug cargo with hydrophobic qualities. The HNPs to date have 
reported only the delivery of hydrophilic compounds, this is because surface 
decoration of the metallic nanoparticles with high levels of lipophilic compounds 
results in them crashing out of solutions as precipitates. Therefore, the only way to 
utilise these nanoparticles and benefit from their inherent properties for lipophilic 
drug molecules is to incorporate into larger macromolecular systems such as 
amphiphilic polymers (Barnett et al. 2013). 
3.1.1 Hybrid iron oxide core gold shell nanoparticles (HNPs)  
The HNPs adopted in this study is consist of both gold as the exposed shell and iron 
oxide as a core (Barnett et al. 2013; Hoskins et al. 2012): The magnetic aspect of the 
iron oxide core allows imaging potential whilst the gold shell which can be exploited 
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for its heating potential as well as allowing a biocompatible exterior for drugs to attach 
onto.  
In order to achieve this core-shell structure a poly(ethylenimine) cushion is inserted 
between the iron oxide core and gold shell. PEI is a cationic polymer containing 
multiple amino groups each separated by two carbon atoms. Attachment of this 
cationic polymer onto the electronegative gold surface results in a positively charged 
surface, this allows attachment of tiny gold seeds before subsequent coating. 
However, PEI holds another purpose other than logistics. Studies have shown that the 
direct coating of gold onto the MNPs results in magnetic quenching possibly due to the 
electron migration of the gold coat into the iron oxide core. Hence, adding this 
polymer cushion maintains the inherent magnetism of the MNP core allowing 
exploitation in MR Imaging. 
Gold nanoparticles have been widely reported in the literature for cancer therapy both 
as drug carriers and alternative approaches to cancer therapy. Colloidal gold possesses 
an interesting phenomenon known as surface plasmon resonance. At a specific 
wavelength irradiation of these particles with light results in the absorption and 
scattering of photons. The process of absorption results in a rapid transfer from light 
energy to heat energy. This results in the nanoparticle heating which is being 
investigated widely for thermal ablation. The HNPs we propose to use in this study 
exhibit this exciting potential, these can be irradiated by light within the near infrared 
wavelengths which allow focussed nanoparticle heating without destruction of local 
tissue. This heating can be tuned dependant on irradiation time and laser power, a 
characteristic which can be used to exploit release of drug compounds. 
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HNPs have shown to bind and release positively charged drug molecules upon heating 
(Malekigorji et al͘ ϮϬϭϳͿ͘ In Malekigorji͛s study, bisnaphtalimido drug molecules with 
polyamine chains within the backbone were able to attach and release dependant on 
the extent of charge at elevated temperature. These findings will form the basis of our 
complex system. In our work we plan to fabricate the HNPs and incorporate them into 
an amphiphilic polymer for the delivery and triggered release of a doxorubicin 
analogue. The focus of this chapter will be the synthesis and characterisation of the 
HNPs and incorporation of these particles into the PAA based amphiphilic polymers 
developed in Chapter 2. For the purposes of this work and all ongoing work we chose 
to work with PAA-Ox5 with estimated molecular weight 17,500 kDa. 
3.2 Research aims  
To synthesize hybrid iron oxide core gold shell nanoparticles (HNPs), monitoring their 
synthesis steps and characterise the final product. To incorporate the HNPs developed 
into the intrinsic PAA-Ox5 structure developed in Chapter 2. 
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3.3 Materials and methods  
3.3.1 Materials used 
Table 3-1 shows the materials which is used in synthesis and description of hybrid iron 
oxide core gold shell nanoparticles. 
Table 3-1 Explain the materials which is used in synthesis and description of hybrid iron 
oxide core gold shell nanoparticles 
Item 
No 
      Material Suppliers 
1 Chloroform Sigma-Aldrich Co., UK 
2 Absolute ethanol Sigma-Aldrich Co., UK 
3 Copper grid Agar Scientific Co., UK 
4 Formvar Agar Scientific Co., UK 
5 Tetrachloroauric acid Sigma-Aldrich Co., UK 
6 Hydrochloric acid Sigma-Aldrich Co., UK 
7 Hydroxyl amine Sigma-Aldrich Co., UK 
8 Iron (II) sulphate ACROS Organics Co., UK 
9 Nitric acid Sigma-Aldrich Co., UK 
10 Polyethyleneimine (Mw = 750000 
gmol-1) 
Sigma-Aldrich Co., UK 
11 Polyethyleneimine (Mw = 2000 
gmol-1) 
Sigma-Aldrich Co., UK 
12 Potassium nitrate ACROS Organics Co., UK 
13 Sodium borohydrate Sigma-Aldrich Co., UK 
14 Sulfuric acid Sigma-Aldrich Co., UK 
15 Sodium hydroxide Fisher Scientific Co., UK 
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3.3.2 Synthesis of iron oxide nanoparticles 
The techniques described by Goon and colleagues were used in this work to synthesize 
HNPs. The first step was to synthesise the iron oxide core through the co-precipitation 
technique (Goon et al. 2009). 
A mixture of 1.03 g NaOH and 1.82 g KNO3 was dissolved in 180 mL of deionised water. 
Nitrogen was bubbled over for 1 h. The mixture was heated to 90 0C with a stirrer. 
3.89 g FeSO4.7H2O was dissolved in 20 mL H2SO4 0.01 M (with sonication). The solution 
was added to the reaction with stirring for 24 h. The particles were then magnetically 
separated from the solvent and washed 6 times with deionised water. The final 
particles were diluted in 25 mL H2O. 
 
3.3.2.1 Coating of iron oxide nanoparticles with Poly(ethylenimine) 
Poly)ethylenimine( (MW 750,000) has been previously utilized to electro- statically 
coat iron oxide NP between the negatively charged magnetic particles and cationic 
polymer. The layer of coating prevents the aggregation of the particles. Essentially, this 
involves adding 5 mgmL-1 of PEI to 50 mL deionised water. This mixture was added to 5 
ml of iron oxide. Thereafter, the mixture was sonicated for 1 h (using Soniprep 150 
plus, MSS150.CX4.5, MSE Co). The particle was magnetically separated and washed 
consecutively 5 times in 30 mL of deionised water to eliminate excess PEI. The final 
particles Figure 3-2 were stored. 
97 
 
 
Figure 3-2: Schematic diagram of iron oxide NPS coated with PEI 
 
3.3.2.2 Gold seeding step  
Gold seeds (2 nm) were made by adding 375 µL (4 % HAuCl4) and 500 µL of 0.2 M 
potassium carbonate K2CO3. The 5 mL solution of sodium borohydride (0.5 mgmL-1) 
was added separately  5 times to 100 mL icy cold water after 10 min. The yellow 
solution changed into a deep red solution. The gold (negatively charged) will interact 
electrostatically with PEI (positively charged) to reach the gold seeding formation. The 
solution was stirred on ice for a further 10 min and then stored in the fridge. 
 The gold seed solution (90 mL) was stirred at room temperature with 2 mL of Fe3O4 of 
PEI solution temperature for 2 h. Then, the HNPs were magnetically separated from 
the solution and washed six times with deionised water. The product particles were 
diluted in 5mL H2O. Gold seeds were protected by stirring the particle with 1 mgmL-1 of 
PEl (2KD) polymer for 10 min. Particles were stirred with (20mL, 1 mgmL-1) PEI 
(MW=2000) solution for 10 min to stabilize gold seeds. After this, particles were 
magnetically and washed six times in deionised water. 
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3.3.2.3 Gold coating process 
The last step of gold to complete coating was achieved by placing the particles in 110 
µL of (0.01 M) NaOH solution and stirring at 60 o C. Hyroxylamine solution (750 µL, 
0.2M) was added followed by 1% HAuCl4 (500 µL). After 10 min 250 µL of NH2OH was 
added and followed by 500 µL HAuCl4 over four iterations. 
The particles were washed 6 times and magnetically separated. The final particles 
resuspended in 5 mL H2O. 
3.3.3 Hybrid nanoparticle characterisation 
3.3.3.1 Transmission electron microscopy (TEM)  
Images of the nanoparticle products of every action in the synthesis of HNPs were 
attained by using a JEOL 1200 EX-FDL5000 microscope (Jeol, Japan) transmission 
electron microscope. Sample preparation involved diluting every sample in deionised 
water and a small amount ;ϭϬ μLͿ was dropped onto a formvar coated copper grid 
(prepared earlier and dried for this objective) and permitted to dry at room 
temperature. The grids were situated into the TEM and directly imaged. 
 
3.3.3.2 Inductively coupled plasma –optical emission spectroscopy 
Inductively coupled plasma-optical emission spectroscopy (ICP/OES) was adopted to 
deduce the amount of both gold and iron in the hybrid nanoparticles formed. The 
instrument used was an Optima 7000 DV ICP-OES (PerkinElmer, Wokingham, UK). An 
acid digestion was performed on the models adopting a mixture of concentrated nitric 
acid and hydrochloric acid ;ϭ͗ϭͿ with heating to ϭϬϬരΣC ;ϭ͗ϱ modal͗ acid mixtureͿ͘ 
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 The result was then diluted alongside deionised water (1:1000) preceding the analysis. 
A calibration was performed adopting usual iron and gold solutions (1000 µgmL-1) 
diluted alongside deionised water (10 µgmL-1 - 0.05 µgmL-1). 
3.3.3.3 UV/Visible spectroscopy  
Iron oxide nanoparticles, nanoparticles following the gold seed step and the final iron 
oxide core-gold shell hybrid nanoparticles (HNPs) were analysed using a Varian Cary 50 
Bio Uv-Vis spectrophotometer over a wavelength range of 300 nm -700 nm in order to 
determine the λmax of the HNPs which was indicative of the surface plasmon resonance 
for heating purposes. UV Peak absorbance was recorded for the aqueous samples in 
deionised water using quartz cuvettes. Uv-Vis absorption spectra were recorded in 
triplicate at room temperature and recorded as an average value. 
3.3.3.4 Photon correlation spectroscopy and zeta potential measurement 
A diluted sample of nanoparticles in deionised water was arranged and sonicated in an 
ultrasonic bath preceding to analysis. Hydrodynamic diameter, polydispersity index 
(PDI) and zeta potential measurements were measured using a Zetasizer Nano-ZS, 
Malvern tools, UK. The calculations were administered at every action of the 
nanoparticle synthesis, all calculations were administered in triplicate at Ϯϱ ̊C and an 
average value was reported. 
3.3.4 Incorporation of HNPs into PAA-Ox5 
A 10 mL solution of 5 mgmL-1 PAA-OX5 was prepared with deionised water as the 
diluent. The polymer solution was probe sonicated for 10 min. To this solution 0.5 mL 
HNPs were added and the mixture was probe sonicated for a further 10 min. 
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3.3.5 Characterisation of PAA-Ox5 and PAA-Ox5-HNP Nano-aggregates  
The macromolecular aggregates were characterised using photon correlation 
spectroscopy and zeta potential measurement as described above. The aggregation of 
these polymers were investigated using surface tension measurement as outlined in 
Chapter 2.  
3.4 Results 
3.4.1 Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP- OES)  
Metal content of the nanoparticles formed was quantified using the technique (ICP). 
The detection wavelengths for gold and iron were measured at 242.794 nm and 
261.187 nm respectively. The  R2 value of gold =  (0.9999) and for iron =( 0.9999) are 
shown in Figure 3-3. Three different batches of HNPs were measured giving the gold 
concentration was 0.22 µg/mL  ±0.1 while the iron concentration was 4.50 µg/mL 
±0.41Figure 3-4. 
 
Figure 3-3: ICP/OES standard calibration curves for A ) Fe and B) Au 
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Figure 3-4:  A graph viewing the concentrations of Au and Fe in HNPs identified by ICP-
OES 
 
3.4.2 UV/Visible spectroscopy 
The absorption spectra of each formulated part in the HNPs was determined at the 
maximum absorption wave length in UV/Visible spectroscopy graph Figure 3-5. The 
MNPs (Fe3O4) alone did not show any absorbance within the wavelengths tested. 
 The colloidal 2 nm gold seeds showed strong absorbance at around 480 nm. Once 
attached onto the Fe3O4-PEI a band shift was observed with a lambda max of 
approximately 540 nm. After subsequent coating the final HNPs showed a peak 
absorbance of 600 nm, this indicated that complete coating had formed Figure 2.7. 
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Figure 3-5: UV ʹVis absorbance spectra of  Fe3O4, Au seed , Fe3O4-PEI and HNPs 
 
3.4.3 Characterisation using TEM 
Characterisation of products from each of the intermediate steps and of the final HNPs 
prepared was undertaken and is described below. 
First step of hybrid nanoparticle formulation started with TEM imaging of iron core at 
150K magnification to verify the average size and morphology which was recorded 
about 40 nm and spherical as shown in Figure 3-6.  
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Figure 3-6: TEM images of A) iron oxide core 
 
The next steps of hybrid nanoparticle formulation was PEI coating of iron core  imaged 
at 120K as shown in Figure 3-7. These look similar to the uncoated iron oxide. This is 
because the electron dense metals appear dark on the TEM whereas polymers are less 
dense, hence it is very difficult to distinguish between these two samples. 
 
 
Figure 3-7: TEM images of iron core-PEI coating 
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The gold seeding processes was confirmed with 2 nm gold nanoparticles surrounding 
the iron core as shown in Figure 3-8 which appeared clearly on the surfaces of NPs at 
200K magnification. 
 
Figure 3-8: TEM image of gold seeded iron NPs 
 
The final shape of HNPs was imaged at 100 K magnification and showed approximately 
particle size around 75 nm. The image of final particles was showed external smooth 
shape with fully gold coated layer and no more appearance was observed for the gold 
seeds Figure 3-9. 
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Figure 3-9: TEM image of final HNPs 
 
3.4.4 Characterisation of PAA-Ox5-HNP  
3.4.4.1 Surface tension 
The data from this test shows that the CAC for the PAA-Ox5 was 0.3125 mgmL-1 
(Chapter 2 ʹ Figure 2-16.) whilst the polymer aggregate incorporating the HNP 
containing amphiphile (PAA-Ox5-HNPs) decreased to 0.039 mgmL-1. This suggested 
that the aggregates formed at lower concentration see Figure 3-10. This may be due to 
the magnetic nature of the HNPs bringing the hydrophobic pendant groups closer to 
one another hence resulting in earlier aggregation compared to the PAA-Ox5. 
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Figure 3-10: Surface tension (N/m) of  PAA-Ox5-HNP(n=3, ave ± SD)  
 
3.4.4.2 Photon correlation spectroscopy 
The charge increased from -8 mV to +26 mV, due to the amine groups in the polymer 
(polycationic PEI) gives the positively charge; this large increase in surface charge is 
indicative of successful polymer attachment (Hoskins et al. 2012). 
After gold seeding the zeta potential dropped to +11 mV and -6.4 mV respectively 
Table 3-2 owing to the electronegative charge on the colloidal gold. The final particles 
coating were recorded with remarkable decrease to -6.4mV and the final particles 
were visualised using TEM  and the particle diameter was determined to be 1221 nm 
as a result of  intrinsic magnetic iron particles.  
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Table 3-2 Zeta potential and PDI, hydrodynamic radius of nanoparticle solution of 
hybrid  nanoparticle synthesis  at different steps 
Particles Hydrodynamic 
radius/ nm 
PDI  
 
 Zeta potential/mV 
Iron oxide 1221   0.328 - 8 
Iron oxide-PEI 800.7 0.420 + 26 
Gold seeded PEI coated 
iron oxide nanoparticles 
649.6 0.587 +11 
HNPs 173.3 0.185  -6.4 
 
Therefore, the diameter of the particles remarkably decreased with the next 
formulation steps of polymer and gold coating related to aggregation reducing abilities 
of magnetic particles Table 3-2. The polydispersity index (PDI) of HNPs referred to the 
homogeneity rate of the distribution of the particles in the formulation, which here 
showed values near 0.3 that detect a good dispersity index rate of this formulation 
Table 3-2. 
Presuming that one thiol aggregation only is tied up to one HNP committing low 
combination of HNP used in conjugation as well as the steric hindrance effect. HNP 
fixed to PAA-Ox5 approved by TEM images which detected as dark curtail parts inside 
nano aggregate Figure 3-11. 
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Figure 3-11: TEM image of PAA-Ox5-HNPs nano-aggregates 
 
3.5 Discussion 
One of the interesting emerging designs in polymer therapeutics is in the incorporation 
of HNPs within PAA-OX5 amphiphilic polymers for form magnetomicelle. These serve 
as multifunctional platforms for imaging and drug delivery (Barnett et al. 2013a). In 
this chapter, the potential of metallic amphiphilic polymer function was used as a drug 
carrier with the ability of incorporation of specific bio-particle to the surfaces of HNP. 
The HNPs were incorporated into PAA-OX5 polymer via dative covalent bonding 
between the gold surfaces and thiol function group of the oxadiazole pendant 
group.  
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Several techniques were used to characterise the synthesis steps of polymer and 
HNP binding by 1H NMR, FTIR, TEM and zeta potential measurements as illustrated 
in  Chapter 2. 
Concerning the synthesis of the hybrid nanoparticles (HNPs), the information obtained 
supports the successful synthesis of the particles. The information created from the 
surface charge measurements correlate the expected pattern, from being negatively 
charged particles for the uncoated iron oxide core (notably, due to the surface 
associated sulphate (Hoskins et al. 2012)) to the positively charged PEI-coated iron 
oxide core, due to the positively charged amino groups inside the PEI construction 
which is covering the iron oxide core. Figure 3-12 displays an appropriate extent of 
particle separation as driven by the devaluation in hydrodynamic radius. 
 
Figure 3-12: Explain PEI-coated iron oxide core 
 
In addition to that, the contradictory charges between the iron oxide core and the PEI 
polymer selected a good sort of charge-charge interaction. 
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 The reduction in surface charge after the inclusion of the small gold seed 
nanoparticles and after the final gold surface application advocates the successful 
coating of the gold outer layer. 
Metal content of the HNPs was exposed by ICP-OES and counted the concentration of 
the gold and iron which is acknowledged as main crucial step in the next biological 
application of the new formulation. UV/Vis spectroscopy information was adopted to 
detect the existence of gold on the surface of the HNPs. Gold nanoparticles show an 
optical characteristic known as surface plasmon resonance (SPR) and the SPR 
wavelength for gold nanoparticles is an observed in the visible region (500 nm - 600 
nm). The magnitude of the absorbing peak and the absorbing shifting was enormously 
dependent on the diameter and form of gold nanoparticles (the absorbing wavelength 
rises alongside a large and variable gold particles) (Huang et al. 2007; Hoskins et al. 
2012). In the end, the TEM images of the starting, intermediate (gold seeding step) and 
the eventual HNPs confirm the successful synthesis. The TEM images also give 
supporting information for the resulting diameter and form of the HNPs: the final 
diameter of the HNPs appears to be inside the range of 100 nm-120 nm and the form 
was approximately stellar as pointed out by the image of the HNPs Figure 3-12. The 
results obtained in this study matched the others reported in the literature (Hoskins et 
al. 2012a). 
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3.6 Conclusion 
Hybrid iron oxide-gold NPs have been successfully formulated and characterized by 
several methods such as PCS, UVʹvis absorption and TEM. All the checking steps 
confirmed the successful formation procedure of hybrid nanoparticles. The magnetic 
iron core with 40 nm diameter was manufactured and other formulated layers were 
diagnosed as a poly(ethylenimine) intermediate layer and gold coating. The last size of 
HNPs was about diagnosed as 100 nm by TEM. These particles were successfully 
incorporated into the PAA-Ox5 structure. This will enable the controllable release of 
hydrophobic drugs through heat trigger. These drug analogues will be synthesized in 
Chapter 4. 
Attachment of doxorubicin to the surface of the HNPs is worth exploring further. Sulfur 
forms dative bonds to the gold surface but it have been shown that electrostatic 
interactions can also be used to attach drug substances to gold. Irradiation of a 
formulation of a polyamine drug derivative coated onto HNPs with near infrared laser 
light triggers drug release. 
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CHAPTER FOUR 
4 SYNTHESIS AND CHARACTERISATION OF DOXORUBICIN ANALOGUES 
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4.1 Introduction  
Cancer is a devastating disease associated with high mortality rates.  The main 
treatment methods for cancer are chemotherapy, surgical treatment, and radiation 
therapy, with the chemotherapy the most commonly used (Zuccala, 2016). In spite of 
this, there are more than 70 types of anticancer drugs which have been used, and a 
variation of new anticancer drug using in clinical trials. However there are many 
problems yet to be solved associated with these chemotherapies, such as aqueous 
drug solubility, side effects from systemic potency, the extend of premature drug 
degradation, and multidrug resistance. To enhance the targeting ability and drug 
solubility, improving the rate and therapeutic effect of the anticancer drugs, the design 
and discovery of reasonable nanocarriers and their targeting drug delivery system has 
received attention (Maeda, 2015). 
 
4.1.1 Doxorubicin 
Doxorubicin((7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,-
9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione 
Figure 4-1 was first extracted from Streptomyces Peucetius Var. Doxorubicin is a drug 
used in therapies for the treatment of many diseases among them lymphoblastic 
leukaemia, non-Hodgkin͛s lymphoma and breast carcinoma (Reddy et al. 2005). 
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Figure 4-1: Structure of doxorubicin 
 
Doxorubicin (Dox) is an anthracycline antibiotic which plays the role of a DNA 
intercalater to restrict topoisomerase II from isolating DNA double helix strands while 
reproducing and therefore stopping the duplication of cells Figure 4-2 (Swift et al. 
2006). Dox is the most antineoplastic operator used in the treating paediatric and adult 
cancer, leukemia, lymphomas, breast carcinoma and many other cancerous tumours 
(Vincenzi et al. 2010) and (Hortobágyi,1997). 
 
Figure 4-2: Doxorubicin intraction into DNA structure (Freeman ,2012) 
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Furthermore, the usage of Dox has been restricted for the dangerous side effects 
which include gastrointestinal disorders bone marrow toxicity, alopecia, stomatitis, 
acute and cumulative cardio-toxicity as well as extravasation (Octavia et al. 2012). 
However, to avoid these limitations and modify the therapeutic potential of Dox 
several approaches have been trialled such as chemical modification (Huang, 2012) 
and loading the drug molecules into nanocarriers such as polymeric micelles (Shan, 
2011) vesicles, liposomes and nano gels (Bochot et al. 2012). The chemical 
modification of Dox forming analogues is crucial for the continued ability to use 
clinically as these analogues can overcome the undesirable side effects whilst 
maintaining clinical efficacy (Oh et al. 2008). The chemical modification can adjust the 
properties of Dox such as lipophilicity, cellular uptake and prolonged activity (Chhikara 
et al. 2010). Substantial work has been carried out in order to form more acceptable 
prodrug and analogue forms of Dox to date (Ding et al. 2012). 
In the present study, we describe the preparation of new doxorubicin analogues by 
coupling of doxorubicin with lipoic acid and doxorubicin with spermine. The results are 
expected to exhibit better effective therapies than anything else previously develop 
4.1.2 Polyamines  
Polyamines are chain like structure which consists of two or more amines. The growth 
of polyamines occurs naturally or is produced by hormone treatment. The naturally 
arising amines (putrescine (C4H12N2), spermidine (C7H19N3) and spermine  (C10H26N4). 
Figure 4-3 are derivatives resulting from the transglutaminase reaction take part in the 
active cell life circle. Polyamine balance within the active cell is related to the growth 
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estimation, therefore, fewer polyamine levels are identified by shrinkage of the cell 
growth (Nowotarski et al. 2013). 
      
         A 
 B
 
 C        
 
Figure 4-3: Structures of naturally occurring polyamines: A spermine ,B spermidine and 
C  putrescine  
 
In addition to that, cancer progression is subjected to be controlled by polyamines, as, 
the highest polyamines level is detected in cancer cells of breast and colon unlike 
normal cell; however, the higher polyamine levels were checked with patients with 
psoriasis, cystic fibrosis (Casero & Marton 2007). Protein synthesis have been shown to 
be triggered by polyamines through provocation of DNA and RNA synthesis due to  its 
responsible for the organization and stabilization of the structure and efficacy of these 
biomolecules (Child et al. 2003) in addition to that stealth of reactive-oxygen species 
by polyamines guides to the conservation of DNA proteins and lipids (Nowotarski et al. 
2013).  
Scientists over the last two decades acknowledge the reticence of the anabolic pathways 
of polyamines. The prevention for anabolic enzymes in the biosynthetic pathway of 
polyamines was checked but none of them gets progressed due to their lower efficacy as 
anti-cancer operator (Casero & Woster 2001).  
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 Profiting of polyamine carrier as an engine to develop the process of rising up of the 
promising anticancer agents by involving the polyamines in their building, was a taking a 
big part of researches pointing the goal to make analogues with better cytotoxic activity 
either added to or being apart from reticence of polyamines biosynthesis (Casero & 
Woster 2001; Muth et al. 2014). 
4.1.2.1  Spermine 
Spermine is a natural polyamine with the molecular formula C10H26N4, which exists in 
many microorganisms as well as in all eukaryotic cells but in different species forms as 
well as different ranges of polyamines. Putrescine, spermidine and spermine are the 
only polyamines produced by mammals (Kusano et al. 2007). 
The structure of spermine was first identified in 1926 by a group of scientists. Antonie 
van Leeuwenhoek had characterized crystals of spermine phosphatein human semen 
in early 1678, while the name spermine was adopted first in 1888 by Ladenburg and 
Abel. Spermine is considered as a polycation at physiological pH and it is the 
constituent that gives the semen fluid its characteristic smell (Pegg et al. 2009). 
Aside from this biological activity spermine is a charged molecule. Its cationic nature 
arises from the amine groups within its backbone. These groups can be exploited for 
reversible binding on the hybrid nanoparticle systems for drug delivery. Malekigorji et 
al. reported the use of a bisnpahthalimido based drug separated by a spermine chain 
which shown reversible binding onto hybrid iron oxide-gold nanoparticles after laser 
irradiation. The system developed enhanced drug efficacy in vivo in pancreatic cancer 
tumours. In this work we adopt this strategy and attach the spermine residue into the 
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Dox molecule to act as a conjugation site for attachment onto the hybrid nanoparticles 
inside the PAA amphiphiles developed in Chapter 3. 
4.1.3 Lipoic acid 
α-Lipoic acid is a type of thioctic acid, consistently presenting aggregation. Lipoic acid 
Figure 4-4 is synthesised enzymatically from octanoic acid in the mitochondria but it 
can also be acquired from Alimentary sources. It has been found to congregate in 
many tissues for a precise period of time. The mixture takes an important role in 
energy metabolism as it performs as a critical co-factor for the α-ketoacid 
dehydrogenase enzyme situated within the mitochondria. However, the data has been 
demonstrating that lipoic acid from dietary sources may not function as a metabolic 
determinant. 
Lipoic acid from dietary supplement is hard to generate key biochemical operation 
which can lead to a possible therapeutic effect. In addition to the antioxidant effect of 
lipoic acid, the mixture has been expressed as part of an administration for controlling 
diabetes and as an aid to enhance age-associated cardiovascular, cognitive, and 
neuromuscular deficits. It has also been displayed to play as a modulator of various 
inflammatory signalling pathways (Biewenga et al. 1997 Packer et al. 1995; Shay et al. 
ϮϬϬϵ͖ Gorąca et al. 2011; Vallianou et al. 2009). 
 
Figure 4-4: Chemical structure of lipoic acid 
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The conjugation of lipoic acid onto the Dox structure will allow for disulphide binding 
onto the hybrid nanoparticle surface which should break down at elevated 
temperatures. 
4.2 Aims and Objectives 
This project aims to synthesize two drug analogues of doxorubicin. The organic 
synthesis will be carried out using established protocols from the literature. Structural 
analysis of the compounds will be carried out using nuclear magnetic resonance, 
Fourier transforms infrared spectroscopy and thin-layer chromatography. 
4.3 Materials and Methods  
4.3.1 Materials 
Table 4-1 shows the materials which is used to synthesize the doxorubicin analogues. 
Table 4-1 Materials used in drug analogue synthesis. 
 Materials Supplier 
1 Doxorubicin HCl LC Laboratories (Woburn, USA) 
2 Spermine Alfa Aesar 
3 Alpha Lipoic acid Sigma Aldrich 
4 N,N-Dicyclohexylcarbodiimide (DCC) Acros organics 
5 Dichloromethane (DCM) Fisher Scientific, UK 
6 Try ethyl amine (TEM)  Fisher Scientific, UK 
7 Methanol Fisher Scientific, UK 
8 N-Hydroxy succinimide (NHS) Alfa Aesar 
9 Carbonyldiimidazole (CDI) Alfa Aesar 
10 Deuterated chloroform Cambridge Isotope Laboratories, Inc. 
11 Deuterated methanol Cambridge Isotope Laboratories, Inc. 
12 Deuterated dimethyl sulfoxide Cambridge Isotope Laboratories, Inc. 
 
120 
 
4.3.2 Method 
4.3.2.1 Coupling of doxorubicin to spermine 
In a round bottom flask (RBF) 1, ϭ഻-Carbonyldiimidazole (CDI) (1.9 mg, 12 mmoL) and 
Dox (0.477mg, 878mmoL) were dissolved in 50 mL of deionized water at 0 °C for 0.5 h . 
After this time spermine (2.4 mg, 12mmoL) was added to the mixture and stirred at 
room temperature for 24 h. The reaction was monitored by TLC. The organic phase 
was evaporated to yield a dark red solid with a yield of 47 %., MP 174-175 o C 
Figure 4-5. 
 
Figure 4-5: Synthesis of doxorubicin ʹspermine Reagents and conditions: deionized 
water, stirrer, 24 h 
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4.3.2.2 Coupling of lipoic acid to doxorubicin 
This reaction has two steps, the first step was made to activated the lipoic acid.  
4.3.2.2.1 Activated the lipoic acid (step 1) 
In a round bottom flask (RBF) lipoic acid (0.713mg, 3.45mmoL) was dissolved in 20 mL 
dichloromethane (DCM). Dehydration agent N, N-Di cyclohexyl carbodiimide (DCC) 
(0.66 mg, 3.19 mmoL) and (0.367 mg, 3.19 mmoL) N-hydroxysuccinimide NHS were 
added to the mixture. The reaction was stirred for 24 h at room temperature. The 
result of the mixture was filtration to remove the solvents leaving a solid Yellow 
precipitate with yield 86% Figure 4-6.  
 
Figure 4-6: Activated the lipoic acid , Reagents and conditions: ethanol absolute  
reflux, stirrer, 24 h 
 
4.3.2.2.2 Doxorubicin coupling to lipoic acid (step2) 
In a round bottom flask, doxorubicin (0.3258mg. 0.5994 mmoL)  was dissolved in 25 mL 
of MeOH and adding to the (0.182mg. 0.48 mmoL) product (step1),  the tryethylamine 
(TEA) (0.32 mL) was added to drop wise the reaction mixture,  and the reaction was 
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refluxed at R.T for 24 h. The solvent was removed leaving a solid dark red residue with 
yield 81% and MP 71-72 o C Figure 4-7. 
 
 
Figure 4-7: Reaction between doxorubicin and lipoic acid, Reagents and conditions: 
ethanol absolute reflux, stirrer, 24 h 
 
4.3.2.3 Characterisation of Doxorubicin analogues 
4.3.2.3.1 Melting point 
The melting point for each doxorubicin derivative was determined using an Advanced, 
Digital, Melting Point / SMP3 (Bibby Sterilin LTD, UK). Determination the melting point 
of each derivative was carried out in a pre-sealed (one end) capillary tube to hold 
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modals, full of 0.1 g-0.2 g of dry mixture. The sample tubes situated then in the melting 
point apparatus. The temperature was slowly elevated and the point at which the solid 
melted was recorded.  
4.3.2.3.2 Thin Layer Chromatography (TLC) 
Chromatography is a method used to separate chemical mixtures. There is a multitude 
forms of the chromatography such as: Thin layer chromatography (TLC), Gas 
chromatography (GC), Column liquid chromatography (CLC) and high performance 
liquid chromatography (HPLC) (Thammana, 2016). 
TLC is a simple experiment which can be adopted in the laboratory to control reactions 
by checking whether the reaction is complete or not, decide the number of 
components in a blend, labelling of compounds or indicate their purity (Coskun, 2016, 
Yua et al. 2016). Chromatography contains a variety of the methods that depend on 
different distribution of the components of the substance to be separated into  two 
phases: the first one stays fixed and called the stationary phase which can be either 
solid or liquid, and the second phase is called mobile phase which can be either liquid 
or a gas (Coskun, 2016). 
TLC is carried out by spotting a sample on a silica gel coated sheet of aluminium as 
displayed in Figure 4-8. These TLC plates re then put in a shallow pool of an eluent 
solution to Inspect the dissolution of materials within the response mixture. The 
retardation factor (Rf), which describes in Equation 4-1, value was forecasted as the 
distance travelled by the unrecognized substance (a) detached by the distance 
travelled by the solvent through the TLC plate (b). Information attained with this 
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method was used to select the best solvent system for column chromatography 
(Coskun, 2016). Rf value is calculated as: 
        
Equation 4-1 Retardation factor 
 
 
Figure 4-8: Diagram of TLC procedure 
 
4.3.2.3.3 13C NMR Spectrum 
Carbon-13 (13C) nuclear magnetic resonance most commonly known as carbon-13 NMR 
or 13C NMR or often simply attributed as carbon NMR) is the usage of nuclear magnetic 
resonance (NMR) spectroscopy to carbon. It is analogous to proton NMR (1H NMR) and 
permit the labelling of carbon atoms in an organic molecule just as proton NMR 
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recognizes hydrogen atoms. As such 13C NMR is an essential tool in chemical structure 
explanation in organic chemistry. 13C NMR identify only the 13C isotope of carbon, 
whose natural abundance is only 1.1%, because the principal carbon isotope, 12C 
(Chemguide,2014). 
4.3.2.3.4 Mass Spectrometry 
The drug analogues were sent to Cardiff University and analysed by MALDI using a 
Bruker ultrafleXtreme instrument in positive-reflector mode with DCTB matrix (aprotic; 
molecular ions possible, any protonation could derive from HCl within the sample, any 
sodiation likely derives from ubiquitous sources). 1:1 MeCN: H2O solution. 
4.4 Result 
4.4.1 Characterisation of doxorubicin -spermine derivative 
4.4.1.1 TLC analyses of doxorubicin-spermine  
TLC analysis of the DOX-SP mixture was carried out to clarify its purity. A drawing of 
the TLC plate is shown in Figure 4-9. The Rf value of this compound is 0.66 mm in a 
methanol ʹ dichloromethane (1:9) solvent system. A single spot indicate the reaction 
had reached completion and eliminated the need for further purification. 
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Figure 4-9: TLC plate of doxorubicin coupling to spermine (DOX-SP) post workup 
4.4.1.2 FT-IR spectrum of doxorubicin – spermine 
Peak assignment of the FT-IR spectra obtained for the DOX-SP Figure 4-10 confirmed 
the coupling of the drug with spermine. This was due to the presence of the hydroxyl 
band at O-H (3254.09 cm-1) and the N-H (2937.64 cm-1) and 2906.67 cm-1 of the 
primary amine, these groups were not present in the spectra for DOX  alone and 
therefore this change in peak can be attributed to the drug molecule. Full peak 
assignment can be noticed in Table 4-2. 
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Figure 4-10: FT-IR spectra obtained for the DOX-Spermine 
Table 4-2 Summary of functional of DOX-SP. 
Compound code Functional group Bond 
Frequency, cmʹ1  
Functional group 
DOX-Spermine 
(DOX-SP) 
 
Alcohol 
Secondary amines 
O-H Stretch 
N-H Stretch 
3254.09 
Alkanes C-H Stretch 
2906.67 
2937.64 
Carbonyl C=O Stretch 1612.46 
Alkenes ʹC=Cʹ stretch 1638.99 
Secondary amines NʹH bend 1377.56 
Aromatics 
CʹC stretch (inʹ
ring) 
1574.97 
Alkenes =CʹH bend 1065.43 
Aromatic amines CʹN stretch 3000-3100 
Alkanes CʹH bend 850.22 
Aliphatic amines CʹN stretch 1280.10 
Alkenes =CʹH bend 1406.21 
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4.4.1.3 1H NMR spectrum of Doxorubicin with spermine 
The 1H NMR spectrums Figure 4-11 of Dox-spermine show the spermine group at the 
following position: 1.1 ppm and 2.5 ppm. The spectrum displays Dox peaks at 7.5 ppm 
-8 ppm, corresponding to aromatic protons in Dox. The spectrum also indicates signal 
at 1.25 ppm which are characteristics of the methyl groups in Dox. The signals at 1.68 
ppm, 1.88 ppm, 2.95 ppm, 4.75 ppm and 5.5 ppm were attributed to aliphatic cyclic 
protons. 
 
 
Figure 4-11: 1H NMR spectrum of doxorubicin with spermine in DMSO carried out using 
400MHz NMR at 25 °C 
 
4.4.1.4 Mass Spectrometry 
This sample Dox-SP Figure 4-12 was analysed by MALDI ʹMass Spectrometry. In the 
spectra there is evidence for the expected molecule, MW=727, from the presence of a 
[M+Na]+ peak at m/z 750.4 a.u., other species were observed which may have chlorine 
associated as would be expected from a polyamine Figure 4-13. 
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Figure 4-12: Doxorubicin coupling to spermine 
 
 
Figure 4-13: Mass spectra of DOX-SP 
4.4.1.5 13C NMR Spectrum of DOX- SP 
The 13C NMR Spectrum of DOX-spermine is shown in Figure 4-14-C. Aliphatic 
hydrocarbons (-CH2) were appearing between 23 ppm ʹ 47 ppm Figure 4-14-a, 
aromatic carbons group between 121 ppm ʹ 136 ppm. Amide group (O=C-N) was 
appear at 72 ppm Figure 4-14-b.  
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Figure 4-14: 13C NMR spectrum of (c) DOX-SP (c), (a) Aliphatic hydrocarbons, (b) Amide 
group of DOX in DMSO- carried out using 400MHz NMR at 25 °C 
 
4.4.2 Characterisation of Doxorubicin – lipoic acid derivative 
4.4.2.1 TLC analyses of doxorubicin-lipoic acid 
TLC analysis of the DOX-LA combination post workup was carried out to explain its 
purity. An diagram of the TLC plate is showed in Figure 4-15. (A) Start materials which 
have two spots with two Rf. The Rf value of (B) mixture is 0.77 in an Ethyl Acetate -
Petroleum Ether (6:1) solvent system. 
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Figure 4-15: Chromatogram of TLC plate of DOX-LA,(A) step 1, (B) step 2  
 
4.4.2.2 FTIR spectrum of Doxorubicin – lipoic acid 
FTIR has been utilize to study the coupling of DOX with lipoic acid. FTIR spectra of DOX-
lipoic acid are presented in Figure 4-16 and characteristic peaks are tabulated in 
Table 4-3. 
FTIR spectrum of DOX-coupling to lipoic acid shows the alcoholic OʹH stretching band 
at 3357.92 cmо 1 and 2936.18 cmо 1. The peaks of NʹH stretching vibrations and OʹH 
stretching vibrations intersection. From this FTIR result, it can be interpreted that 
attachment of DOX to lipoic acid occurs by the interaction of ʹNH2 groups of DOX with 
ʹOH groups of lipoic acid group hydrogen bonding. 
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Figure 4-16: FT-IR spectra of doxorubicin with lipoic acid (DOX-LA) 
Table 4-3 Summary of functional of DOX-LA. 
Compound code Functional group Bond 
Frequency, cmʹ1  
Functional group 
DOX-lipoic acid 
(DOX-LA) 
 
Alcohol 
Secondary 
amines 
O-H Stretch 
N-H Stretch 
3365.21 
Alkanes C-H Stretch 
2947.88 
2935.77 
Carbonyl C=O Stretch 1722.88 
Alkenes ʹC=Cʹ stretch 1611.40 
Secondary 
amines 
NʹH bend 1403.88 
Aromatics CʹC stretch (inʹring) 1574.63 
Alkenes =CʹH bend 1085.37 
Aromatic amines CʹN stretch 3000-3100 
Alkanes CʹH bend 761.37 
Aliphatic amines CʹN stretch 1260.06 
Alkenes =CʹH bend 1340.33 
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4.4.2.3 1H NMR spectrum of DOX-LA 
Doxorubicin derivatives were characterised using 1H NMR spectroscopy. The 1H NMR 
spectrum Figure 4-17 of Dox-Lipoic acid shows the lipoic group at the following 
position: 1.4 ppm, 1.64 ppm, 1.5 ppm, 2.3 ppm, 2.4 ppm, 3 ppm, 3.5 ppm. The 
spectrum displays peaks at 7.5 ppm -8 ppm, corresponding to aromatic protons in 
Doxorubicin. The spectrum also indicates signal at 1.25 ppm which are characteristics 
of the methyl groups in doxorubicin. The signals at 1.68 ppm, 1.88 ppm, 2.95 ppm, 
4.75 ppm and 5.5 ppm were attributed to aliphatic cyclic protons. 
 
Figure 4-17: 1H NMR spectrum of doxorubicin-lipoic acid in DMSO carried out using 
400 MHz NMR machine at 20 o C 
 
4.4.2.4 13C NMR Spectrum of Doxorubicin-lipoic acid (DOX-LA) 
The  13C  data acquired for DOX-LA  Figure 4-18 aliphatic hydrocarbons (-CH2-) appear 
between 23 ppm ʹ 48 ppm Figure 4-18-b with aromatic carbons group from the 
doxorubicin between 121 ʹ 136 ppm. The amide groups (N-C=O) were observed at 164 
ppm Figure 4-18-a. The -CH2 groups present in the lipoic acid were inverted, between 
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33 ppm ʹ 40 ppm, and the quaternary carbons, for instance the carbonyl peak from 
the amide (164 ppm) had disappeared. 
 
Figure 4-18: 13C NMR spectrum of (c) DOX-LA (c), (a) Aliphatic hydrocarbons, (b) Amide 
group of DOX in DMSO- carried out using 400MHz NMR at 25 °C 
 
4.4.2.5 Mass Spectrometry 
Figure 4-19 shows the structure of the Dox-LA which was analysed using mass 
spectrometry. 
 
Figure 4-19: Chemical structure of coupling DOX-LA 
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This sample Figure 4-19 was analysed using a Waters Xevo G2-S instrument. There 
was evidence of a [M+H]+ signal at 732.2457 a.u. but this was accompanied by 
significant fragmentation using this solid insertion technique Figure 4-20. 
 
Figure 4-20: Mass spectra of coupling DOX-LA 
 
4.5 Discussion  
A multitude of other coupling reactions between doxorubicin and various linkers have 
been reported but unfortunately none of them resulted in favourable yields. Strategies 
for the formation of amide link bond coupling agents have been explored (Montalbetti 
& Falque 2005; Valeur& Bradley 2009) and a remarkable multitude of these 
procedures were adopted in small scale test in order to discover a strategy that gave 
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the elevated yield. These trials were in addition to the essential trial that had been 
tried to optimise the simple protocol applied originally in the synthesis of doxorubicin 
analogues.  
The data presented shows that the two doxorubicin analogues in this work were 
successfully synthesized (PAA-Ox5-HNPs-DOX-SP and PAA-Ox5-HNPs-DOX-LA). 
Spermine was coupled with Dox by using a (1,1'-Carbonyldiimidazole) CDI as a coupling 
regent using laboratory conditions and confirmed to be prepared to adopt NMR, FTIR, 
and 13C NMR with a yield (47 %).  
Doxorubicin was also coupling with lipoic acid to obtain doxorubicin containing a 
combination of sulfur and (N,N'-Dicyclohexylcarbodiimide) DCC as a connecting 
operator. The preparation is confirmed utilizing FTIR, NMR, Mass, and 13C NMR 
measurements with yield (81%). The yields obtained in this work give promise to the 
field in the respect that it is possible to form doxorubicin analogues in sufficient 
quantities to make them worthwhile candidates for further evaluation as 
chemotherapies. 
The doxorubicin analogues synthesised in this chapter will be used to couple  onto the 
PAA-Oxadiazole-HNP magnetomicelles formed in Chapter 3 and their ability to 
encapsulated and release the analogues at varied temperatures will be evaluated in 
Chapter 5. 
4.6 Conclusion 
Synthesis and characterisation of doxorubicin analogues in sufficient yields was 
successful as characterised by various techniques. Subsequently these analogues will 
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be formulated and tested for their efficacy enhancement on pancreatic cancer cells in 
vitro. 
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CHAPTER FIVE 
5 INCORPORATION OF ANALOGUES INTO POLYMERIC SYSTEMS AND POTENTIAL IN CANCER THERAPY 
 
 
 
 
 
139 
 
 
5.1 Introduction 
Cancer is a deadly disease characterised by uncontrolled tumour growth and spread to 
other parts of the body. Pancreatic cancer is particularly devastating due to its late 
diagnosis and lack of treatment options (Banerjee et al. 2005). Therefore, new 
treatment regimes are required. The scientific utility of doxorubicin (DOX) is limited by 
its serious side effects. Persisting efforts are pursued at evaluating effective DOX-
delivery systems that might control the disadvantages of present ones. In the current 
report, we document a self assembling prodrug making elevated drug loading 
nanoparticles for DOX delivery (Gou et al. 2013). 
One option for these is the use of amphiphilic polymers as drug carriers as discussed 
elsewhere in this thesis. One drawback to using this technology is its constant state of 
dynamic equilibrium, where control over release is unachievable. Often in the use of 
these technologies in cancer therapy, the phenomenon of enhanced permeability is 
relied on whereby the particles accumulate in the tumour tissues offering a degree of 
site specificity. In this chapter we incorporate the drug analogues synthesised in 
Chapter 4 into our amphiphilic poly(allylamine)-oxadiazole-HNP construct. This will 
allow for electrostatic binding of the drug molecule onto the HNP within the aggregate 
core, which can only be reversed at elevated temperatures.  Hence this system will 
confer a greater degree of drug release. In order to achieve such elevated 
temperatures, our HNPs within the polymer constructs will be irradiated with laser, the 
ability of these HNPs to heat upon laser irradiation has been reported in the literature. 
(Malekigorji et al. 2014).  
140 
 
All new drug carriers or active ingredients are required to undergo a series of 
preclinical testing before they can be considered for in vivo and clinical trial (Aulton 
2007). Hence, we carried out preliminary in vitro testing of our novel formulations on 
human pancreatic cancer cell lines. Such studies enable the elucidation of whether 
these new formulations are an improvement on the existing drug treatment options.  
Biological systems are a group of intricate chemical systems and microenvironments 
which could possibly have effect on alive ingredients and their component. Hence, new 
drug formulations have to be noticed in chemical environments that can mimic these 
physiological conditions (Wijdeven et al. 2014; de la Escosura et al. 2015). 
These environments might comprise the diverse biological pH͛s such as blood and the 
gastrointestinal tract (Lemke 2008; Aulton 2007). These are repeatedly examined 
separately to completely understand their effects on the drug formulation being 
examined without the intervention of different changing chemical, such as examining a 
new drug in a series of biological such as changing the temperature, concentration etc. 
In vitro examinations which were established on adopting cell and tissue cultures that 
proliferate outside the body in laboratory environment are repeatedly used to check 
the toxicity and efficiency of potential drug or chemicals molecules (Sonali etal, 2015). 
However, in vivo examination is needed to appropriately identify the in vitro data 
inadequate (James, 2008). 
In the current experiment, pancreatic cancer cells (BxPC-3) were adopted as a sample 
cancer in order to examine the capability of our copolymer formulations to boost 
cancer chemotherapy.  
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5.1.1 MTT assay 
The MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
reduction   assay is a commonly used assay in the cytotoxicity evaluation of new drug 
entities.  The MTT assay used to assess cytotoxicity, activation and proliferation by 
measuring the signal resulting from living cells, which is dependent on the level of 
activation of the cells (Mosmann, 1983, Terry et al., 2013, Kumaravel and Begum, 
2015). 
The MTT assay Figure 5-1 is based on the conversion of MTT into formazan crystals by 
living cells which determines mitochondrial activity. 
 In most cell populations, the total mitochondrial activity is linked to the number of 
viable cells. This assay is used to measure the in vitro cytotoxic effects of drugs on cell 
lines or essential patient cells. 
 
Figure 5-1: Chemical structure of MTT 
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5.2 Research aims 
The objective of this chapter is to Incorporation of analogues doxorubicin into 
polymeric systems and analyse the interaction of doxorubicin-spermine and 
doxorubicin-lipoic acid along the surface gold of the HNPs. Subsequent examination 
into the potential for the nanoparticulate formulation to heat responsive drug delivery 
system in vitro necessary drug loading and drug release experiments to be set in 
motion, monitored by HPLC and potential in cancer therapy. To determine the 
cytotoxicity effect of formulations of HNPs, PAA-OX5-DOX-LAHNPs and PAA-OX5-DOX-
Spe-HNPs on the BxPC-3 pancreatic cell lines utilizing the MTT assay.  
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5.3 Materials and Methods 
5.3.1  Materials used 
Table 5-1 shows the materials used in corporation of analogues into polymeric and  
biological investigations. 
Table 5-1 Materials used in corporation of analogues into polymeric and  biological 
investigations. 
 Materials   Suppliers 
1 Doxorubicin (DOX) LC Laboratories (Woburn, USA) 
2 DOX-Spermine Synthesised in Chapter Four 
3 DOX-Lipoic acid Synthesised in Chapter Four 
4 Poly(allylamine)  PAA 17.5 kDa Synthesised in Chapter two 
5 Orthophosphoric acid Sigma-Aldrich Co., UK  
6 Acetonitrile Sigma-Aldrich Co., UK  
7 PRMI culture medium   Life technologies Co., UK 
8 Trypsin-EDTA 0.05   Life technologies Co., UK 
19 Foetal bovine serum  Fisher Scientific, UK 
10 Penicillin streptomycin  Life technologies Co., UK 
11 Cell freezing medium   Sigma-Aldrich Co., UK 
12 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) 
Sigma-Aldrich Co., UK 
13 of dimethyl sulfoxid   DMSO  Fisher Scientific, UK 
14 Hybrid nanoparticles (HNPs)   Synthesised in Chapter Three 
15 BxPC-3 cell line (Passage number:10)   LGC Standards Co., UK 
16 Phosphate buffered saline Fisher Scientific, UK 
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5.3.2  Methods 
5.3.2.1 Drug conjugation 
5.3.2.2 HNP-DOX-Spermine and HNP-DOX-Lipoic acid loading into polymer 
A 10 mL solution of 5mgmL-1 PAA-Ox5 was prepared with deionised water as a diluent. 
The polymer solution was probe sonicated for 10 min. To this solution, 500 µL of HNP-
DOX- Spermine and HNP-DOX-Lipoic acid were added separately and the mixture was 
probe sonicated for 10 min. The resultant solution was filtered using 0.45 µm syringe 
filters and preparing to additional analysis. The drug loading of each formulation was 
calculated by using HPLC analysis.  
 
5.3.2.3 Quantification of doxorubicin 
An accurate amount of doxorubicin hydrochloride was weighed in order to prepare 1 
mgmLʹ1 stock standard solution in methanol Figure 5-2. 
 
Figure 5-2: Calibration curve of doxorubicin at R.T 
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To identify the optimal loading concentration of every drug on the HNPs, the amount 
of drug attachment was quantified by reverse phase high performance liquid 
chromatography RP-HPLC (Prominence, DEGASSER, LC20AD, SHIMADZU) utilizing a 
fluorescence indicator at 480 nm (Excitation) and 560 nm (Emission) (Jasco, PU-980, 
Japan; column C18(2), 150 mm ×4.60 mm 5 micron, flow rate: 1 mLmin-1, injection 
volume: 20 µL). The buffer applied in HPLC mobile phase was arranged by adding 10 
mmoL ammonium hydrogen phosphate((NH4)2HPO4)(to boost the retention) and 5mL 
trimethylamine(C3H9N) to 200 mL of deionised water. Then the pH of the solution was 
adjusted to 4.0 with orthophosphoric acid (H3PO4). The mobile phase was a mixture of 
buffer pH 4.0/acetonitrile(C2H3N )/methanol(CH3OH) (60:24:16, V/V/V), sonicated for 
10 min (Toshniwal ultrasonic cleaner, India) and filtered through 0.45 µm filter. 
R20.9988. the regression equation obtained is:  y = 7.524X + 0.0573. 
5.3.2.4 In vitro drug release study in aqueous media 
Formulations (2 mL, 0.5 mgmL-1) were placed into visking tubing (12-14 KDa) and 
dialysed against 100 mL deionised water at different temperature ;ϮϬ ˚C, ϯϳ˚C, ϰϰ˚C) 
along stirring͘ The volume of dialysis fluid was in excess to mimic the ͚sink͛ setting 
examined after injection into the blood stream (Barnett et al. 2013a). At chosen time 
points (1 min, 5 min, 10 min, 0.5 h, 1 h, 2 h, 3 h, 4 h and 24 h) a sample of the exterior 
solution (1 mL) was taken off and changed with 1 mL deionised water at the stated 
time points previously described. All models were diluted with 1 mL of deionizes water 
and drug concentrations were examined via HPLC. The investigation was carried out in 
triplicate and the peak area was compared to a calibration of the free drug.  
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5.3.3 Biological characterisation of nano-aggregates and formulation 
5.3.3.1 MTT([3-(4,5-Dimethylthiazol-2-yl)2,5DiphenyltetrazoliumBromide]) 
cytotoxicity assay  
Human pancreatic adenocarcinoma BxPC-3, cells (3 mL, 15000 cells/well) in their 
exponential growth phase were seeded into 96-well plates and incubated for 24 h at 
37 °C with 5 % CO2. A 20 mgmL-1 stock solution was prepared of each DOX formulation 
(and free drug). From this stock solution eight dilutions (0.1 mgmL-1 - 1×10-5 mgmL-1)  
using media as the diluent were prepared Table 5-2. 
Table 5-2 Preparation of Excipient Solutions for MTT assay 
Drug concentration  
(mgmL-1 ) 
Volume of 20 mgmL-1 
drug stock solution 
;ʅLͿ 
Total volume of media 
(mL) 
0.1 22.5 4.5 
0.05 11.5 4.5 
0.025 6.5 4.5 
0.01 2.25 4.5 
0.005 1.125 4.5 
*0.001 90 4.5 
*0.0001 9 4.5 
*0.00001 1 4.5 
* Sample was made from 0.05 mgmL-1 concentration as a stock solution. 
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After 24 h, the formulations were removed and replaced with fresh media (100 µL). 
MTT  3-[4, 5-dimethylthiazole-2-yl]-2, 5-diphenyl tetrazolium ; ϱϬ μL, ϱ mgmL-1 in PBS) 
was  added to the wells and then the plate  was incubated (37 °C with 5 % CO2) for 4 h. 
Next, the solution of MTT was removed from the wells. The purple formazan was 
remaining complexes were dissolved in ;ϭϬϬ μLͿ DMSO͘ At 570 nm, the absorbance of 
the plates was read using a microplate reader (Tecan, infinite 200 pro, GmbH 5082, 
Australia). IC50 and Percentage cell viability was calculated relative to the negative and 
positive controls (no cell treatment and complete cell lysis using 2% Triton-X). All 
studies were run in triplicate (n=3) and the average values were recorded. 
 
5.3.3.2 In vitro thermo-responsive cytotoxicity assay 
To indicate whether laser irradiate could be used for triggered drug release the MTT 
assay was repeated with one amendment. After exposure to formulation (1 h), the 
plates were incubated at 44°C (as a thermal variant that can mimics the heat 
generated by the surface plasmon resonance (SPR) of laser irradiated HNP gold 
coatings) for 0.5 h, before being replaced into the incubator at 37 °C with 5 % CO2 for 
rest of the 24 h period.  
5.4  Results 
 
5.4.1 Drug conjugation 
Conjugation of drugs by electrostatic attachment onto the surface of HNPs has been 
previously reported. The conjugation of DOX-SP and DOX-LA onto the HNPs in the 
presence of PAA-Ox5 was achieved successfully. The drug loading of each formulation 
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was calculated by using HPLC analysis. The value loading of HNP-DOX-SP to the PAA-
OX5 was 3.301 and for the HNP-DOX-LA loading to the PAA-Ox5 were 3.7. 
 
5.4.2 Drug release of PAA-Ox5-HNPs- DOX-SP at different temperatures 
Conjugation of drugs by electrostatic attachment on the surface of HNPs is a new 
strategy to transfer therapeutic agents towards their site of action͘ The drug release 
profile was at first decided at ϮϬ ̊C before conducting analysing the effect of heat on 
the release profile of doxorubicin analogue from the PAOx5-HNPs-DOX-SP and PAA-
Ox5-HNPs-DOX-LA structures. 
The percentages of burst release in the first hour of the analysis display there is no 
release in the drug at 20 oC Figure 5-3. Then one hour later the percentages of drug 
release had started to appear, at 4 h was (2.16 %),  the drug release was reported (3.38 
%) the utmost drug release occurred at 24 h. 
 
Figure 5-3: Drug release of PAA-Ox5-HNPs-DOX-SP at 20 o C over 24 h(n=3)(SD±) 
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At 37 o C the percentage of drug release was recorded (17.15 %) after only 4 h. At 24 h 
the percentages of drug release was recorded (30%) which was the highest 
concentration at 37 oC Figure 5-4. 
 
Figure 5-4: Drug release of PAA-Ox5-HNPs-DOX-SP at 37 o C over 24 h (n=3) (SD±) 
 
At 44 o C the percentage of drag release was shown (23.72 %) after 4 h, at 24 h the 
percentages of drug release was recorded (49.11%) Figure 5-5. This result was 
indicating the effect of heat in drug release formulation of PAA-Ox5-HNPs-DOX-SP. 
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Figure 5-5: Drug release of PAA-Ox5-HNPs-DOX-SP at 44 o C for 24 h (n=3)(SD±) 
 
5.4.3 Drug release of PAA-Ox5-HNPs- DOX-LA  at different temperatures 
Drug release for formulation of PAA-Ox5-HNPs-DOX-LA was recorded lower 
percentages than drug release for formulation of PAA-Ox5-HNPs-DOX-SP , this was due 
to the number of amine group of spermine N-H. 
At 20 o C the percentage of drag release was shown (1.16 %) after 4 h . After 24 h the 
percentages of drug release was recorded (1.98 %) which was the highest 
concentration at 20 o C Figure 5-6. 
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Figure 5-6: Drug release profile of PAA-Ox5-HNPs-DOX-LA at 20oC over 24 h (n=3)(SD±) 
 
Figure 5-7 shows the highest percentage of drug release at 37 o C was noted (23.64 %)  
after 24 h. This was greatly reduced compared with the spermine-DOX release profile. 
 
Figure 5-7: Drug release profile of PAA-Ox5-HNPs-DOX-LA at 20oC over 24 h (n=3) (SD±) 
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Doxorubicin analogues release was analysed at 44 °C to mimic the temperature of the 
environment around HNPs and after laser irradiation with near-infrared light. 
Figure 5-8 shows the drug release of PAA-Ox5-HNPs-DOX-LA at 44 o C which is 
recorded the higher release rates of doxorubicin at (39.64%) over 24 h.  
 
Figure 5-8: Drug release profile of PAA-Ox5-HNPs-DOX-LA at 20oC over 24 h (n=3)(SD±) 
 
5.4.4 Biological characterisation of nano-aggregates and formulation 
Cell viability of BxPC-3, incubated with unloaded HNPs was determined using the MTT 
assay. The MTT assay is a commonly used assay in the cytotoxicity evaluation of new 
drug entities. The concentrations displayed in the chart for HNPs are identical to the 
concentration of hybrid formulations but evidently without drug (the concentrations of 
Fe in HNP and hybrid formulations are similar). Overall, both cytotoxic evaluations 
show comparable results and the HNPs did not demonstrate a cytotoxic effect on cell 
viability over the concentration ranges tested.  
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Percentage cell viability for PAA-Ox5-HNPs, doxorubicin alone, PAA-Ox5-HNPsDOX-SP  
and PAA-Ox5-HNPs-DOX-LA at 24 h were compared. Figure 5-9 shows there was no 
IC50 observed for PAA-Ox5-HNPs after 24 h. There was however a reduction in cell 
viability at the higher concentrations possibly due to the cationic nature of the PAA 
conferring a slight degree of cytotoxicity. 
The IC50 observed for PAA-Ox5-HNPs-SP after 24 h was 48 µgmL-1, while the IC50 
obtained for PAA-Ox5-HNPs-LA after 24 h was 53.3µgmL-1 . This was an improvement 
compared to the free drug which did not present any IC50 value. This increase in 
cytotoxicity compared with the free drug is possibly due to the cellular uptake of the 
drug in greater quantities once inside the PAA nanoaggregates. Multiple studies have 
shown that once encapsulated inside polymeric micelles, endocytosis enables greater 
quantities of cellular uptake of drugs compared with the unformulated molecules. 
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Figure 5-9: MTT assay graph show the effect of various concentrations of doxorubicin, 
PAA-Ox5-HNPs ,PAA-Ox5-HNPs-DOX-SP and PAA-Ox5-HNPs-DOX- on BxPC-3 cells  in 37 
o C at 24 h time points (n=3) (±23%) 
At high temperature 44o C Figure 5-10, the cell viability for PAA-Ox5-HNPs resulted in  
an unexpectedly large reduction in  the cell viability, the reason for which is unknown, 
further studies are needed in order to validate this finding. PAA-Ox5-HNP-DOX-SP 
possessed a notable reduction in the cell viability, where an IC50 was observed at 25 
µgmL-1 after 24 h, which was a 2-fold reduction compared to the value observed at 
body temperature. This indicated that the threshold energy required to break the 
electrostatic binding between the HNP and drug had occurred resulting in the free 
drug being able to exert its toxic effect on the cell more efficiently. 
Similarly, PAA-Ox5-HNPs-DOX-LA showed a 2-fold improvement in IC50 at 0.025 µgmL-1 
at 44 oC temperature, whilst the free drug possessed an IC50 at much higher 
concentration of 85 µgmL-1. Both formulations showed a great improvement 
compared to DOX at both temperatures observed indicating that the formulation has 
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potential in pancreatic cancer therapy. However, more work is required to further 
understand the biological interactions with cells both in vitro and in vivo. 
 
Figure 5-10: MTT assay graph show the effect of various concentrations of doxorubicin, 
PAA-Ox5-HNPs ,PAA-Ox5-HNPs-DOX-SP and PAA-Ox5-HNPs-DOX- on BxPC-3 cells  in 44 
o C at 24 h time points (n=3) (±23%) 
 
5.5 Discussion 
Polly(allylamine) amphiphiles have been reported for drug solubilisation previously. 
However, conferring heat triggered release into these systems have not yet been 
explored. Conjugation of drugs by electrostatic attachment onto the surface of HNPs 
has been previously reported. In this work we combined the use of PAA amphiphiles 
with HNPs.  
 In a different experiment, Barnett and co-workers made and assessed a new class of 
(PAA) polymer conjugated with hydrophobic oxadiazole (Ox5) pendant group.  
They advised that the thiol-containing pendant group can augment the attachment of 
HNPs by dative covalent connection. Various drugs were conjugated along with direct 
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conjugation of hydrophilic and encapsulation of hydrophobic drugs. In contrast with 
the free drug, the conjugated drugs had remarkable elevated drug uptake with 
diminished IC50 (Barnett et al.2012)  Figure 5-11 and Figure 5-12.  
In order to deliver doxorubicin analogues in the treatment of pancreatic cancer. Drug 
loading into the amphiphiles was achieved as confirmed by HPLC. Generally speaking, 
loading capacity of drugs is affected by a number of determinants such as feeding 
concentration, the number of amine group, the existence of thiol group and PAA and 
the type of interaction between drug and HNPs (electrostatic or covalent). In a 
different experiment, Aslam and co-workers clarified that gold has a strong affinity 
about the amino group (Aslam et al. 2004).  
 
 
 
Figure 5-11: Explain interaction of positive amine groups of doxorubicin with the gold 
coating 
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Figure 5-12: Theoretical imagination of doxorubicin ʹspermine and -lipoic acid coupling 
to the surface of the hybrid iron oxide core gold shell nanoparticles 
 
The drug release profiles were observed at varied temperatures from the PAAOx5-
HNPs-DOX-SP and PAA-Ox5-HNPs-DOX-LA structures. In vitro heat treatment and drug 
release of the drug analogues formulated into PAA-Ox5-HNPs-DOX-SP was attained, 
3.38 % of release DOX was released over Ϯϰ h at room temperatures. The particles 
displayed Fickian dispersal release kinetics, 49.11% was the maximum drug released 
noticed at 44 °C after 24 h. In vitro analysis displayed also presented that 42.12. % of 
the total drug content was released after 24 h at 37oC (Purushotham et al. 2009) 
Figure 5-13. 
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Figure 5-13: Drug release of PAA-Ox5-HNPs-DOX-SP in deferent temperature (n=3) 
(SD±) 
The formulation of PAA-Ox5-HNPs-DOX-LA  was recorded  1.98% of release dox was 
released over the period of Ϯϰ h  at room temperatures Figure 5-14. The particles 
displayed Fickian dispersal release kinetics, 38.64% was the maximum drug release 
noticed at 44 °C after 24 h. In vitro analysis displayed also presented that 23.64 % of 
the total drug content was released after 24 h at 37oC (Purushotham et al. 2009). 
0
10
20
30
40
50
60
0 500 1000 1500 2000
%
 R
el
ea
se
  
Time min 
PAA-17.5 kDa-Ox5-DOX-Sp 
159 
 
 
Figure 5-14: Drug release of PAA-Ox5-HNPs-DOX-LA in deferent temperature (n=3) 
(SD±) 
MTT assay was used to determine the cytotoxicity of the doxorubicin analogue on 
human pancreatic adenocarcinoma (BxPC3) cells. The unloaded nano-aggregates were 
incubated for 24 h with the cells and the cell viability was compared to control wells. 
The result revealed that 50% of the total cell number was viable (IC50) at 50 mgmL-1 
(PAA-Ox5-HNPs). These values revealed that the incorporation of the metallic HNPs 
into the polymer backbone did not result in any significant increase in toxicity 
(p>0.001). 
MTT assays were achieved on doxorubicin, PAA-Ox5-HNP, formulation of (PAA-Ox5-
DOX-SP-HNP and PAA-Ox5-DOX-LA-HNP construction to decide If the formulation of 
doxorubicin analogues were able of transfer cytotoxic drugs into the cells, thus 
boosting their therapeutic effect. To decide if the novel formulation boosted the 
therapeutic effect of their anticancer drug, they were encapsulated at the polymer IC90 
concentration (the concentration at which 90% of cells were viable). 
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In order to examine the effect of temperature on cell cytotoxicity, the IC50 was decided 
for the heat operating plates and compared to the non-operating plates. In general, 
heat treatment did not conclude in a significant effect on cytotoxicity of PAA-OX5-
HNPs. This work confirms the heat triggered system developed resulted in more 
efficient DOX delivery compared to free drug and drug at body temperature. Due to 
the detrimental side effects experienced after DOX administration it often cannot be 
used in already ill pancreatic cancer patients. Therefore, this work offers an exciting 
alternative where drug can be tracked real-time using MRI guidance and laser 
irradiation could be used to release the drug localised within its desired site hence 
reducing systemic toxicity and side effects. More work is needed in vitro to further 
elucidate cellular response as well with laser irradiation to further investigate the 
systems potential. 
5.6 Conclusion 
Doxorubicin with amine group was able to conjugate with HNP; however, stronger 
interaction of drug-NPs was achieved by increasing the number of amine from 
doxorubicin to DOX-SP (four amine groups). Conjugation of DOX-LA with HNPs 
confirmed that exploiting Au-S chemistry is possible for conjugation of a molecule 
possessing thiol group to the gold coating surface. By connecting doxorubicin to lipoic 
acid to afford a method to connect the prodrug to the gold surface of the HNPs nano 
particles may offer various advantages. It may heighten the action of doxorubicin as a 
result of site-specific activity or augmenting the amount of drug entering the 
circulation considering the overall physicochemical properties of the drug analogue. In 
addition to that, the effect applied by the lipoic acid residue of the prodrug might 
influence the activity of the prodrug and the quantity of doxorubicin released 
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(Geromichalou et al. 2015). The addition of polyamine (spermine) or lipoic acid and 
coupling of the PAA-Ox5 to the HNPs could improve the efficacy of doxorubicin 
therapy. The data showed that the coupling of doxorubicin to spermine resulted in an 
increase in the rate of drug application also.  
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6.1 General Conclusion 
This study showed that hydrophobic oxadiazole groups were capable of attachment 
onto via conjugation to the primary amines of a PAA backbone.  
Many studies have been carried out in the literature regarding other cationic polymers 
such as poly(ethylenimine) and their role in self-assembly after modification of 
hydrophobic subunits. However, little has been explored for PAA. Preliminary work in 
this study showed that in general increasing molecular weight of polymer resulted in a 
higher extent of drug loading as tested at 15 kDa,17.5 kDa 120 kDa and 900 kDa PAA. 
This finding was in agreement with other studies reported on other cationic polymers. 
(Shen et al,2015). However, with higher drug loading comes other properties such as 
larger sizes, instability of aggregates, release profiles, etc. A study by Barnett shows 
that drug release is a significant characteristic of a therapeutic system (Barnett et al. 
2013). Where scientists found a linear linker between the drug release and the 
absorption of the body. (Lu et al. 2011). In this work, the drug release was influenced 
by polymer molecular weight and drug loading. Polymers with higher molecular weight 
tend to possess slower drug release compared to lower molecular weight. The 
molecular weight of the polymer can significantly effect the degree of aggregation, the 
solubility of higher molecular weight polymer in solvent was less than that of lower 
molecular weight polymer. Therefore, the heavier polymer would precipitate out 
faster and the molecular chain would be hardened by not allowing the intermolecular 
interaction of the drug layers around the particles which would cause aggregation 
(Kung ,1997).  
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Taking our findings into account, looking at the surface tension data, the aggregates 
formed at high molecular weight are likely to be more unstable upon dilution. Hence, it 
was decided to continue our studies throughout this thesis on PAA-Ox5 with molecular 
weight of PAA as 17,500 kDa.  
The rationale for using oxadiazole within the polymer comb structure was in order to 
later attach inorganic nanoparticles into the system. These hybrid iron oxide-gold 
nanoparticles (HNPs) have previously been exploited for thermally triggered thermo-
responsive drug delivery applications (Malekigorji et al. 2017). However, due to the 
weight and solution stability of these molecules, such applications could only be 
exploited for aqueous soluble compounds.  
Barnett et al. showed that these HNPs could be irreversibly be incorporated into the 
core of the core-shell polymeric aggregates in aqueous environments via dative 
covalent binding between the thiol residue in the oxadiazole and the gold HNP surface 
(Barnett et al. 2013). Once the HNP was located within the newly formed 
magnetomicelle structure this could be exploited as a site of attachment for insoluble 
drug compounds within the lipophilic core of the polymeric aggregate. Hence this 
system was developed in order to give safe-passage of the doxorubicin analogues 
created enabling a heat triggered mechanism for site specific delivery of this highly 
toxic molecule. 
The synthesis of the HNPs was shown to be successful by determining the 
physicochemical features of the particles, size, shape and efficient coating of the iron 
oxide core of the hybrid system by using multitude techniques that include photon 
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correlation spectroscopy, zeta potential dimensions, inductively coupled plasma-
optical emission spectroscopy (ICP-OES) and transmitting electron microscopy (TEM).  
Another objective was to synthesis of two doxorubicin derivatives. The synthesis of a 
doxorubicin derivative supporting a cationic polyamine chain (spermine) designed 
following on from the Malekigorji work (Malekigorji et al. 2014) Here they reported 
the use of electrostatic chains in the reversible heat cleavable binding of novel drug 
molecules ʹ with a bisnaphthalimido based drug with a spermine linker being the most 
successful. Hence, spermine was used to conjugate onto the doxorubicin for the initial 
drug analogue. Malekigorji et al. ;ϮϬϭϳͿ indicated that the effect of heat ;ϰϰ ̊C) might 
shift the drug HNPs binding if the connection was an electrostatic charge interaction 
(Malekigorji et al. 2017). 
The analogue was successfully synthesised and analysed using FTIR, NMR 13C NMR and 
Mass spectroscopy with a yield of 47%. The goal of the synthesis of the DOX-SP was to 
supply an arm with doxorubicin to actively cohere to the gold surface of the HNPs 
while granting the ability of the system DOX-SP-HNPs-PAA-OX5 to operate as a stimuli-
responsive carrier. 
 
The second analogue was based on the conjugation of lipoic acid onto the doxorubicin. 
In previous studies in our group lipoic acid was shown to form a disulphide linkage with 
the gold HNP surface which cleaved at elevated temperature and reduced pH (data not 
published). In this work, synthesis of the doxorubicin analogue bearing a sulfur-
containing residue was achieved by using amide bond union of doxorubicin to lipoic 
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acid. The profitable synthesis and reaction level up was completed by using simple two 
steps reaction and the prime conditions for the reaction were concluded. The region 
selectivity of the union of doxorubicin to lipoic acid by amide bond structure was one 
of the advantages of utilizing DCC as a unifying operator that supplied only one 
product with a just yield of 81%. The aim of the synthesis of the DOX-LA was to supply 
an arm with doxorubicin to actively cohere to the gold surface of the HNPs, while 
granting the capability of the system DOX-LA-HNPs-PAA-OX5 to operate as a stimuli 
responsive carrier. 
Loading of the DOX-SP and DOX-LA onto the surface gold of the HNPs was tested at 
various concentration ratios and a maximum loading concentration of 5 mg of DOX- 
per 1 mg HNPs (Fe) and 5 mg of DOX-LA per 1 mg HNPs (Fe) was accomplished 
successfully. In vitro heat treatment and drug release of the drug analogues 
formulated into PAA-Ox5-HNPs-DOX-SP was attained, 3.38 % of released DOX was 
released over 24 h at room temperatures Figure 5. 14. The particles displayed Fickian 
dispersal release kinetics, 49.11% was the maximum drug release noticed at 44 °C after 
24 h. In vitro analysis displayed also presented that 42.12. % of the total drug content 
was released after 24 h at 37 °C. The formulation of PAA-Ox5-HNPs-DOX-LA was 
registered 1.98% of release dox was released over the duration of 24h at room 
temperatures. The particles displayed Fickian dispersal release kinetics, 39.64% was 
the maximum drug release observed at 44 °C after 24h. In vitro analysis showed also 
demonstrate that 23.64 % of the total drug content was released after 24 h at 37 °C. 
The final formulations acquired in the biological part of this experiment were used.  
MTT assay was adopted to decide the cytotoxicity of the doxorubicin analogue on 
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human pancreatic adenocarcinoma (BxPC-3) cells. The unloaded nano-aggregates were 
incubated for 24 h with the cells and the cell viability was set to manage wells. The 
outcome displayed that 50% of the total cell number was active (IC50) at 50 gmL-1 (PAA-
Ox5-HNPs). These values displayed that the unification of the metallic HNPs into the 
polymer backbone did not issue in any remarkable increase in toxicity. 
MTT assays were used to evaluate the change in viability of BxPC-3 cells after exposure 
to the novel formulation and the effect of temperature on cell cytotoxicity. The IC50 
was determined for the heat activated plates and compared to the non-activated 
plates. In general, the data showed that the heat activation resulted in more efficient 
drug efficacy compared to free drug and drug at body temperature with no associated 
toxicity from the HNPs ʹ experiments were carried out at the polymer IC90. Due to the 
damaging side effects DOX induces in pancreatic cancer patients, it often cannot be 
used as a treatment option. Therefore, this work provides an interesting alternative 
where drug can be tracked real-time using MRI instruction and laser irradiation could 
be employed to release the drug situated within its desired site hence reducing 
systemic toxicity and side effects.  
This study serves as a proof of principle, however a lot more work is required to 
further understand and optimise these systems before clinical translation could occur. 
The drug loading/release profiles required further tailoring in order to improve drug 
efficacy in vitro and a greater improvement on heat activation would possibly result ʹ 
helping to provide further rationale for using this complex system. Repeatable scale-up 
of the preparation is required, perhaps this could be achieved through the use of 
microfluidics which seems to be revolutionising the liposome domain. More work is 
168 
 
required in vitro to further interpret cellular response as well with laser irradiation to 
further examine the potential of the system. Additional cell lines would be required 
such as Panc-1, pancreatic panel cell lines as well as healthy cell lines and fibroblasts 
which may mimic better the extracellular matrix.  In vivo target ability, permeability, 
accumulation and fate are ultimately required which could be conducted using 
xenograft mice similar to Malekigorji͛s work. Finally, GMP good manufacture Practice 
must be employed in order to produce suitable formulations for clinical trial. 
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